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Abstract 
 
The aim of this thesis is to examine the neuropsychological profiles of psychosis 
patients, with and without current cannabis use. Specifically, to determine how age may 
moderate the effects of cannabis use on neurocognition. In normal populations, cannabis 
use, whether previous or current, has been shown to provoke deficiencies across a range of 
cognitive domains, specifically verbal memory, executive functioning, working memory, 
and psychomotor functions. However, patients diagnosed with a psychotic disorder, in 
particular, non-affective psychosis (i.e. schizophrenia-spectrum disorder), who have a 
history of, but no longer engage in, cannabis use, demonstrate cognition that is seemingly 
superior to their peers who have no history of cannabis use at all. While studies generally 
report that drug-naïve schizophrenia-spectrum patients demonstrate a range of cognitive 
deficiencies compared to the general population, patients with a history of cannabis use, in 
some cases, exhibit neurocognition similar to control subjects. There are three predominate 
theories that address the unique findings of this clinical group. Initially, comorbid psychosis 
patients were thought to display social cognition that was better than their drug-naïve 
counterparts as explanation for the abilities required to source and obtain the drug. However 
comorbid patients tend to display poorer premorbid functioning initially, which is often an 
argument against this theory. Alternatively, another theory suggests cannabis use instead 
promotes a neuroprotective effect in such patients. Previous studies have found increased 
concentrations of neurotrophins, specifically brain-derived neurotrophic factor (BDNF) 
and nerve growth factor (NGF), in psychosis patients with a history of cannabis use. As 
neurotrophins primarily induce the development and function of neurons, this finding 
indicates cannabis may demonstrate neuroprotective properties in psychosis patients. 
However, imaging studies have demonstrated loss of brain volume in first-episode patients 
who use cannabis, which is inconsistent with a neuroprotective effect. Thus, the objective 
of the present thesis was to explore the third theory – that vulnerable individuals instead 
bring about their own psychotic illness through cannabis use and represent a subgroup of 
patients who are less cognitively compromised than patients who would develop a 
psychotic disorder despite cannabis use. 
The studies in this thesis focus on several tests of neuropsychological functions. 
Interchangeably referred to as neurocognitive tests, these assessments are commonly used 
in clinical settings to measure functioning of particular pathways and structures in the brain. 
Neuropsychological tests are critical in patient diagnoses, as well as monitoring the 
progression of disorders. The domains covered in this thesis include general intelligence, 
working memory, verbal learning, attention, and executive functions, including set-
shifting, processing speed, and visuospatial function. Previous studies generally conclude 
cognitive decline follows a first-episode of psychosis, with patients consistently 
underperforming across tests of visual memory, visuospatial functions, attentional set-
shifting, working memory, as well as a number of executive functions. The relatively 
numerous cognitive deficiencies observed across psychoses patients, specifically 
schizophrenia-spectrum psychosis, as compared to healthy individuals, brings about the 
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notion of a global cognitive deficit being fundamental in a non-affective psychosis 
diagnosis. In the case of this thesis, neurocognitive comparisons between psychosis patients 
with and without current cannabis use is a central theme.  
 Lifetime prevalence rates of a psychotic disorder is generally 3%, while 
schizophrenia-spectrum disorders remain steady around 1%, with greater prevalence in 
developing countries and low socioeconomic areas. Male to female ratios of schizophrenia 
and other psychoses, although initially believed to be equal, have been shown to be 
relatively higher in males. Interestingly, females exhibit better recovery rates, including 
significant fewer remissions and better global cognitive functioning at follow-ups. 
However, concurrent cannabis use by patients has consistently shown to be greater in male 
patients, who also tend to have a younger age of illness-onset, and greater duration of 
untreated psychosis. The highest incidence of a first episode of psychosis is between 16 
and 25 years of age, with men typically being diagnosed with a psychotic disorder as young 
as 18 years. The incidence of cannabis use among psychosis patients has been reported to 
be as high as 60% and is significantly more prevalent among this group than healthy 
populations. Interestingly, both psychosis- and drug use-onset seem to occur around the 
same time, with young people typically between the ages of 15 and 24 years experimenting 
with cannabis for the first time. With most previous research examining lifetime cannabis 
use in adult patients, typically in the more chronic stages of schizophrenia, studies instead 
reporting on neurocognition during this critical time of both illness- and drug use-onset are 
highly warranted.  
Young people represent an ideal population to follow, in regard to neurocognition 
in psychosis. Not only is adolescence and young adulthood the typical period for both 
illness- and drug use-onset, but they are also a population less likely to be exposed to other 
critical environmental factors such as chronic use of antipsychotic medication. Most 
research demonstrates superior cognition in older schizophrenia patients who have a history 
of cannabis use, compared to drug-naïve patients. Thus, it is critical to investigate the 
neurocognition in patients at the time of psychosis-onset, before both cannabis cessation 
and medication initiation, to explore potential alternate pathways to non-affective 
psychosis. 
 The studies presented in this thesis represent the first to address 
neuropsychological differences in psychosis patients with and without current cannabis use 
exclusively in young people (i.e. between 16 and 25 years of age). These findings are 
subsequently implicated in contributing to the paradoxical results of adult patients with a 
history of cannabis use. There have been no reported investigations of neurocognition in 
young non-affective psychosis patients with current cannabis use, and subsequent 
regression models examining their relationship with adult patients. Both young and adult 
psychosis (i.e. non-affective) patients have routinely been reported as having global 
cognitive deficiencies compared to healthy controls. Contradictorily, adult patients with a 
history of cannabis use demonstrate superior cognition compared to their drug-naïve peers, 
yet very little is known about the cognition of patients during both illness- and drug-onset. 
In order to further explore the theory of cannabis inducing one’s illness, and ultimately 
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displaying spared cognition, research observing patients at this critical ‘window of 
vulnerability’ is warranted. 
The first study of this thesis (i.e. Chapter 2) is a meta-analysis that investigates 
neuropsychological data reporting on current cannabis-using psychosis patients and 
compared patients in studies exploring either first-episode psychosis (FEP) or specifically 
schizophrenia. It was hypothesized that cannabis-using psychosis patients would 
demonstrate significant deficits across a range of neurocognitive tests, compared to non-
using patients. Additionally, age was expected to moderate cognition. Specifically, younger 
cannabis-using patients were expected to demonstrate superior neurocognitive 
performance compared to older cannabis users, older non-users, and younger non-users. As 
the majority of research on psychosis patients primarily involves adults, more specifically 
patients over the age of 25, this study also aimed to evaluate cognitive differences between 
younger and older patients. Regression models were subsequently executed to analyse 
effect of age on neurocognition results. A literature search was performed to identify 
studies comparing psychosis patients with and without current cannabis use. Of the 308 
studies identified through database searches and secondary referencing, 14 were selected 
to be included in the meta-analysis. It was found that current cannabis-using patients 
underperformed across 6 of the 11 cognitive domains (i.e. premorbid IQ, current IQ, verbal 
learning, verbal working memory, motor inhibition) compared to cannabis-naïve patients. 
Cannabis-using patients however outperformed non-users in tests of conceptual set-
shifting. Meta-regressions showed older age in cannabis-using patients was predictive of 
worse performance in processing speed, sustained attention, verbal memory, and better 
performance in verbal learning and verbal fluency. These findings parallel previous studied 
indicated current users demonstrate poorer neurocognition than cannabis-naïve patients. 
Importantly, it appears this is exacerbated with increasing age. There also appears to be 
significant cognitive differences between patients even at early-onset psychosis, suggesting 
underlying processes involved in psychosis cognition. 
In the second study (i.e. Chapter 3), psychosis patients were exclusively between 
16 and 25 years of age. The young patients underwent neurocognitive assessments to 
compare cognition between drug-naïve patients and concurrent cannabis-using patients, to 
further explore the above-mentioned third theory of an alternate pathway to schizophrenia. 
It was expected comorbid psychosis patients and cannabis-naïve patients would 
demonstrate no significant neurocognitive differences. Subjects were 24 cannabis-using 
and 79 cannabis-naïve psychosis patients. Patients, and 63 healthy controls, were 
administered a neurocognitive battery, indexing estimated pre-morbid intelligence, 
psychomotor speed, mental flexibility, verbal learning and memory, verbal fluency, 
sustained attention, motor and mental response, and visuospatial learning and memory. The 
findings indicated no significant neurocognitive differences between the two clinical 
psychosis groups, despite one group concurrently engaging in cannabis use. Thus 
suggesting underlying neurobiologyical mechanisms involved in regulating cognition in 
the cannabis-using psychosis group.  
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The elucidation achieved by this approach parallels previous research that suggest 
a vulnerable subgroup of patients bring about their own illness, and so are cognitively 
spared compared to patients who are diagnosed regardless of such external factors. The 
first study (i.e. Chapter 2) demonstrated worse cognitive functioning across concurrent 
cannabis-using patients compared to drug-naïve patients. However, meta-regression clearly 
displayed the cognitive results were moderated by age. This was particularly important as 
the majority of studies in this area focus on older, more chronic cases of psychosis or 
schizophrenia, and this moderation by age showed the significance in focusing on young 
people, particularly when both illness- and drug use-onset occur. This was further explored 
in the second study (i.e. Chapter 3), which demonstrated that at this critical age (i.e. 
between 16 and 25 years of age), current cannabis-using patients exhibited no cognitive 
deficiencies compared to non-users. This is particularly remarkable as it contrasts with 
studies of healthy cannabis-using populations, as well as older cannabis-using patients.  
Ultimately, previous studies reporting superior cognition in patients with a history of 
cannabis use, and the current thesis demonstrating no cognitive differences between 
patients regardless of concurrent cannabis use, taken together indicate this concept of an 
alternate pathway to adult schizophrenia.
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Chapter 1 
1. Introduction 
1.1 Neurocognition in Patients with Psychosis 
Over the past 20 years, cognitive deficiencies have been regarded as a core feature 
of psychoses disorders, particularly schizophrenia-spectrum and non-affective psychosis 
(Reichenberg et al., 2009). Mounting evidence has demonstrated a range of cognitive 
impairments from mild, almost-normal cognition, to dementia-like intuition (Kremen, 
Seidman, Faraone, Toomey, & Tsuang, 2000) across a range of  cognitive domains. 
Although there is considerable heterogeneity across individuals, psychosis patients tend to 
most prominently exhibit cognitive deficits across domains of memory and learning, 
executive functions, processing speed and attention (Holmén, Juuhl-Langseth, 
Thormodsen, Melle, & Rund, 2010; Reichenberg et al., 2010; Saykin, Gur, Gur, & et al., 
1991; Wilk et al., 2005). There has been a recent push to realize the substantial range of 
cognitive deficits as viewed in schizophrenia as reflecting a global cognitive deficit, 
implying that cognitive impairments across domains share a neurobiological source. 
Deficits across tests of working memory remain fairly common in psychotic patients and 
imply significant disturbances in the dorsolateral prefrontal cortex (DLPFC), and its 
interactions with other neural structures, in psychosis (Edwards, Barch, & Braver, 2010; 
Lesh, Niendam, Minzenberg, & Carter, 2011).  
However, despite any heterogeneity among patients, neurocognitive discourse 
appears to be consistent across cultural and geographic variations, as well as time. Schaefer 
and colleagues conclude a substantial, generalized impairment is consistently found in 
schizophrenia compared to controls, in studies across three decades, and several countries 
(Schaefer, Giangrande, Weinberger, & Dickinson, 2013). Importantly, moderate to large 
effect sizes were demonstrated across all cognitive domains in first-episode psychosis 
(FEP), with a greater magnitude of deficit in older, more chronic patients. Previous theories 
have addressed schizophrenia as a neurodegenerative disorder to explain this phenomenon, 
as well as neurotoxicity as a consequence of the disease itself. Recent studies suggest the 
length of psychotic state after commencing treatment may be predictive of functional and 
structural decline (Andreasen, Liu, Ziebell, Vora, & Ho, 2013; Davis et al., 1998; Neeltje 
et al., 2007). Furthermore, relapses early on in the illness seem to be a potent predictor of 
neurocognitive deterioration in later years. However, a number of longitudinal studies 
demonstrate that schizophrenic patients instead exhibit stability in neurocognition, and in 
some incidences, small improvements, over time (Hoff, Svetina, Shields, Stewart, & 
DeLisi, 2005; Stirling et al., 2003b). A longitudinal study found that FEP patients 
demonstrated greatest neurocognitive change before hospitalization, and remains relatively 
stable afterwards (Hoff et al., 2005). Patients did not deteriorate significantly compared to 
controls at the 10-year follow-up period, indicating cognitive change occurs early on in the 
illness. In many cases, neurocognitive deficits are observed long before the presentation of 
clinical symptoms in patients, indicating the significance of neurocognitive functioning in 
understanding the pathogenesis of schizophrenia. Rund and colleagues have also concluded 
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that evidence is lacking for both the neurotoxicity and neurodegenerative theories of 
schizophrenia (Rund et al., 2016). Their mixed model analysis of a 10-yearlong sample 
shows neurocognitive stability in patients over time. Interestingly they also found, 
however, that those with stable remission in the first year had better neurocognitive 
trajectory in the follow-ups than patients who remained continuously psychotic after the 
first year. Perhaps this subgroup represents a less severely ill phenotype that responds well 
to treatment and has a good prognosis, including a good neurocognitive trajectory. 
Ultimately, research into the course of neurocognition in schizophrenia shows treatment 
response in the first year is a key variable, predicting the long-term course of 
neurocognition. Most surprisingly, patients generally display no significant cognitive 
deterioration compared to controls, after treatment.  
 It is crucial, however, to note heterogeneity across psychosis patients may be due 
to separate diagnostic subgroups. Both empirical and meta-analytic studies have 
demonstrated distinct cognitive impairment in schizophrenia-spectrum and affective-
psychoses disorders. The findings typically show worse neurocognition in schizophrenia 
patients compared to affective psychoses, with small to moderate effect sizes (Barch, 2009; 
Barch & Sheffield, 2014; Bora, Yucel, & Pantelis, 2009; Bora, Yücel, & Pantelis, 2010). 
Meanwhile the current literature on schizophrenia and schizoaffective disorders is mixed, 
with some studies concluding greater cognitive deficiency in schizophrenia (Torniainen et 
al., 2012; Xiao, Bartel, & Brekke, 2017), and some reporting no differences between the 
two (Heinrichs, Ammari, McDermid Vaz, & Miles, 2008; Sözeri-Varma et al., 2011). 
Regardless of the larger magnitude of cognitive impairment in schizophrenia compared to 
affective psychoses, the current literature consistently demonstrates greater cognitive 
deficits in both disorders compared to controls. Reichenberg and colleagues best 
demonstrate this result in their recent study measuring neurocognition in patients diagnosed 
with schizophrenia, schizoaffective disorder, bipolar disorder, and major depressive 
disorder. They found that although schizophrenia patients demonstrated significantly worse 
cognition compared to the other three groups across all domains, all four groups had 
comparable neuropsychological performance profile patterns, and exhibited impairments 
in memory, executive functions, and attention and processing speed (Reichenberg et al., 
2009). Ultimately, all psychoses (affective and non-affective) are associated with some 
level of cognitive impairment. This impairment may be equally severe in schizophrenia 
and schizoaffective disorder, and less so in patients with psychotic bipolar and psychotic 
major depressive disorder. However, the profile or pattern of cognitive impairment across 
affective psychoses is very similar to that seen in schizophrenia. This finding supports the 
notion of common underlying mechanisms across psychoses disorders and validates the 
concern to pinpoint core neurobiological structures and pathways that transcend psychosis 
diagnoses.  
1.2 Neurocognition in Psychosis Patients with Previous Cannabis Use 
Cannabis use has been shown to mediate subsequent psychotic illness in vulnerable 
individuals, however the relationship between substance abuse and outcome remains 
unclear. As many as 64% of patients with schizophrenia use cannabis (Barnes, Mutsatsa, 
Hutton, Watt, & Joyce, 2006), which appears to have an effect on brain functioning and 
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biochemistry, as well as demonstrate seemingly paradoxical positive effects on cognition 
in patients with schizophrenia (Arnold, Allott, Farhall, Killackey, & Cotton, 2015; Løberg, 
Hugdahl, & Jørgensen, 2007). Longitudinal studies have demonstrated an increased risk 
for schizophrenia and other psychoses after substantial cannabis use. Two large-scale 
Swedish studies, which followed the same cohort of approximately 50 000 military 
conscripts over 15 and 26 years, reported dose-dependent relationships were found between 
cannabis use at 18 years of age and later diagnosis of schizophrenia (Andréasson, 
Engström, Allebeck, & Rydberg, 1987; Zammit, Allebeck, Andreasson, Lundberg, & 
Lewis, 2002). Several other longitudinal studies have also demonstrated a strong 
correlation between adolescent cannabis use and subsequent psychosis in the normal 
population (Arseneault et al., 2002; Ferdinand et al., 2005; Fergusson, Horwood, & Swain-
Campbell, 2003; Henquet et al., 2005; Stefanis et al., 2004; Tien & Anthony, 1990; van Os 
et al., 2002). One possible explanation for the dramatic increase of cannabis use in this 
patient population is reversed causality, in other words, schizophrenia patients may use 
cannabis as a form of self-medication, however current data does not support this 
hypothesis (Chambers, Krystal, & Self, 2001). The most prominent argument against 
reversed causality is an order-effect, essentially, that cannabis use tends to occur before a 
diagnosis of psychosis, rather than the other way around (Degenhardt et al., 2007; Linszen, 
Dingemans, & Lenior, 1994). Several studies have also shown that tetrahydrocannabinol 
(THC), the main psychoactive components in cannabis, increases symptoms of psychosis 
and cognitive impairments (D’Souza et al., 2005; Morrison et al., 2009). Similarly, 
cognitive impairment is often observed before the development of psychosis, as well as in 
close relatives, and is often observed in patients even after clinical symptoms are reduced 
(Bowie & Harvey, 2006). 
 Interestingly, schizophrenia patients who abstain from using cannabis appear to 
ultimately demonstrate neurocognition superior to that of patients who have never used 
cannabis (Burns, 2013; Cuesta, Sánchez-Torres, Lorente-Omeñaca, & Moreno-Izco, 2017; 
Yücel et al., 2012). As previously discussed, schizophrenia and other psychoses patients 
appear to exhibit deficits across several neurocognitive domains. In parallel, individuals 
with long-term cannabis use, who are otherwise healthy, also demonstrate severe cognitive 
impairments, particularly across tests of residual memory and attention, even after 
abstinence (Grant, Gonzalez, Carey, Natarajan, & Wolfson, 2003; Yücel, Solowij, 
Respondek, & et al., 2008). Yucel and colleagues also reported structural brain 
abnormalities in these otherwise healthy, cannabis-users, contributing to their cognitive 
deficits (Yücel et al., 2008). Whereas, meta-analyses have shown that patients with a 
history of cannabis use, often before the onset of psychosis symptoms, actually perform 
better across many cognitive domains, particularly executive functioning, working 
memory, and visual functioning, than patients who do not have a history of cannabis-use 
(Rabin, Zakzanis, & George, 2011; Yücel et al., 2012). Interestingly, Jockers-Scherübl et 
al. also found that earlier onset of cannabis use (i.e. before 17 years of age) coincided with 
even better cognitive performance in schizophrenia patients (Jockers-Scherübl et al., 2007), 
although earlier initiation in healthy controls worsened cognition. This result however is 
not limited to chronic, or long-term schizophrenia patients. Yucel and colleagues replicated 
Jockers-Scherübl et al.’s finding in first-episode patients, demonstrating an earlier-onset of 
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cannabis use in patients is associated with superior cognition even at the first-episode of 
psychosis (Yücel et al., 2012). Schnell et al. have also shown that more frequent use of 
cannabis by patients is associated with superior cognition (Schnell, Koethe, Daumann, & 
Gouzoulis-Mayfrank, 2009a). Unsurprisingly, these contradictory results have brought 
about a rise in research in the neurobiology and underlying mechanisms involved in 
comorbid psychosis patients. One of the most prominent questions that arises through these 
paradoxical results is the presence of alternate pathways to psychosis, through 
environmental, as well as inherent, means.  
1.3 Alternate Pathways to Non-Affective Psychosis 
Several hypotheses exist for the paradoxical superior cognition seen in patients with 
previous cannabis use. It has previously been suggested that cannabis-using patients 
demonstrate superior social skills in order to access the drug, resulting in overall superior 
global cognition (Potvin, Joyal, Pelletier, & Stip, 2008). However evidence for this theory 
remains unconvincing, with Ringen and colleagues reporting patients who use drugs have 
poorer premorbid functioning initially (P. A. Ringen et al., 2008). Some studies have also 
suggested cannabis use, prior to illness onset, instead results in a neuroprotective effect 
(Coulston, Perdices, & Tennant, 2007; Jockers-Scherübl et al., 2007). Significantly higher 
concentrations of neurotrophins have been found in schizophrenia patients with previous 
cannabis use, compared to patients without history of cannabis use (Jockers-Scherübl et al., 
2004; Jockers-Scherübl et al., 2003). Neurotrophins, in particular nerve growth factor 
(NGF) and brain-derived neurotrophic factor (BDNF), are involved in the development and 
maintenance of nerve cells. Perhaps this increase is associated with an endogenous repair 
mechanism, in which the cannabis induces the upregulation of neurotrophins, which in turn 
helps preserve cognitive functioning. This is supported by other clinical studies, which 
show neuroprotective effects of cannabis in both normal and neurodegenerative 
populations (Hampson et al., 2000; Jiang et al., 2005; Ramírez, Blázquez, del Pulgar, 
Guzmán, & de Ceballos, 2005; Yosef & Raphael, 2005). Giuffrida et al. similarly found an 
inverse relationship between cerebrospinal fluid (CSF) levels of the endocannabinoid, 
anandamide, and psychotic symptoms in acute schizophrenia patients (Giuffrida et al., 
2004). This suggests that elevated anandamide levels in acute schizophrenia may reflect a 
compensatory adaptation to the disease. Taken together, these studies indicate some 
neuroprotective quality of cannabis in schizophrenia, which is initially brought on by the 
drug itself.  
 However, the most prominent theory at present surrounds the notion that patients 
who present with psychosis, as well as a history of long-term cannabis use, have brought 
about their illness through early-onset of drug use, which otherwise would not have 
occurred in the absence of cannabis (Løberg & Hugdahl, 2009; Schnell et al., 2009a; Yücel 
et al., 2012). Simply, early cannabis use induces psychosis in less cognitively vulnerable 
individuals. Meanwhile, schizophrenia patients who have no history of cannabis use are 
likely to have greater genetic or developmental vulnerability to psychosis; thus they 
manifest poorer cognitive performance at psychosis onset. This is supported by evidence 
that patients who began using cannabis early in adolescence are at greater risk for 
subsequent psychosis (Arseneault et al., 2002; Yücel et al., 2012), and perhaps ultimately 
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superior cognition to cannabis-naïve patients (Jockers-Scherübl et al., 2007). Ruiz-Veguilla 
et al. also reported that comorbid patients presenting with first-episode psychosis, and who 
had a history of heavy cannabis use, exhibited fewer neurological soft signs than their drug-
naïve counterparts (Ruiz-Veguilla et al., 2009), suggesting these comorbid patients have 
less neurodevelopmental impairment. Ideally, these schizophrenia patients would not 
present with psychosis if they avoided cannabis use altogether. 
 Interestingly, the residual (7 h-20 days after use) and long-term (at least 21 days 
since use) effects of cannabis appear to effect psychosis patients differently to otherwise 
healthy individuals (Broyd, van Hell, Beale, Yucel, & Solowij, 2016; Crean, Crane, & 
Mason, 2011; Curran et al., 2016; Ranganathan & D'Souza, 2006). In healthy individuals, 
acute effects (0-6 h after use) of cannabis show the greatest degree of dysfunction, with 
subjects demonstrating impairment across attention, decision making, impulsivity and 
working memory. However, both residual and long-term effects appear to largely revert to 
near-normal functioning, with a greater abstinence showing the most advanced 
improvement in cognition. In theory, cannabis-using psychosis patients would be expected 
to perform worse than cannabis-naïve patients across several domain functions, paralleling 
the results of healthy individuals. In contrast, evidence suggests patients with a history of 
cannabis use, who now abstain, outperform cannabis-naïve peers in several cognitive 
domains.  
 Several recent studies demonstrate superior cognition in psychosis patients 
mediated by a history of adolescent cannabis use. Hanna et al. reported better global 
cognition in schizophrenia/schizoaffective patients who had engaged in cannabis use 
during adolescence compared to patients with no prior drug use (Hanna, Shalvoy, et al., 
2016). However, this result did not translate to patients diagnosed with bipolar psychosis, 
who instead revealed no cognitive differences between adolescent cannabis users, and non-
users. Løberg and colleagues similarly found schizophrenia patients with a history of 
cannabis use outperformed patients with no history of use across cognitive domains of 
general intellect, executive functions, attention, working memory, and psychomotor speed 
(Løberg & Hugdahl, 2009; Løberg et al., 2007). In a separate longitudinal study, both 
comorbid psychosis patients and drug-naïve patients showed cognitive deficits at 
admittance to a psychosis ward, however comorbid patients demonstrated greater 
neurocognitive improvements three months after admittance (Løberg & Hugdahl, 2009; 
Løberg et al., 2007). Yucel and colleagues similarly researched cognition in a distinctly 
FEP group, with and without a history of cannabis use (Yücel et al., 2012). They found 
patients who began using cannabis earlier on (i.e. younger than 17 years of age) displayed 
superior cognition compared to patients with later drug-onset, which parallel the findings 
of Jockers-Scherübl and colleagues (Jockers-Scherübl et al., 2007). Yucel et al. defined 
their comorbid group as regular cannabis users (i.e. >2 grams/week, >2 years) preceding 
illness onset. With dramatic increase in global cognition so quickly after drug cessation, it 
calls to question the neurocognitive profile of these patients, during illness onset, and 
before drug cessation. Evidently, adolescence represents an especially interesting stage to 
observe as both illness- and drug-onset occur around this time. Unfortunately, due to the 
nature of this study, much of the research observing neuropsychological consequences of 
cannabis use on psychosis patients involves lifetime, but not current, cannabis use, and so 
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tend to focus on adult, but not adolescent, patients. Young patients are at critical age to 
observe cognitive consequences of both drug-use and psychoses disorders at illness-onset 
and for longitudinal studies, to further understand alternate pathways to schizophrenia. 
1.4 Psychosis and Cannabis in Youth Populations 
The study of schizophrenia at the first-episode phase has become more prominent 
for a number of reasons – perhaps most obvious is that earlier treatment leads to better 
outcome (Keefe, Seidman, Christensen, Hamer, & et al., 2004; Keefe et al., 2006; Keefe, 
Sweeney, Gu, Hamer, & et al., 2007; Wyatt, 1991). As previously discussed, much of the 
research on neurocognition in comorbid psychosis patients focuses on older, more chronic 
cases of psychosis, however rarely are adolescents or young people, when both illness and 
drug onset tend to occur, the subject of focus. The incidence of psychosis rapidly increases 
after 15 years of age, with the highest rate of a first episode occurring between the ages of 
15 and 25 years (Amminger et al., 2006; Gillberg, Wahlstrom, Forsman, Hellgren, & 
Gillberg, 1986; Hare et al., 2010). Young people, aged 12 to 24 years, represent an 
important population to study psychotic disorders as such individuals represent a subgroup 
of patients less likely to be exposed to critical environmental factors such as chronic use of 
antipsychotic medication (Epstein et al., 2014). There is also evidence that the corpus 
callosum, part of the highest order, latest maturing network of the brain, continues to grow 
until the middle 20’s (i.e. 25.45 years on average) (Pujol, Vendrell, Junqué, Martí-Vilalta, 
& Capdevila, 1993). This, as well as synaptic pruning, which also continues until the mid-
20’s, suggests full brain development is incomplete until around 25 years of age (Andersen, 
2003). Young people are also at a great risk of substance abuse, particularly those for whom 
the age of onset of drug use (alcohol and cannabis, in particular) occurs prior to around 15 
years of age.  
However, most individuals do not develop schizophrenia after cannabis use, 
suggesting that a heightened risk for a development of psychosis must be related to other 
vulnerability factors. The relationship between cannabis use and psychosis may 
demonstrate a gene by environment interaction. Caspi and colleagues’ longitudinal study 
involved following 803 individuals into adulthood and found a functional polymorphism 
in the catechol-O-methyltransferase (COMT) gene heightened the risk of adolescent 
cannabis use resulting in schizophreniform disorders (Caspi et al., 2005). In accordance 
with this, an interaction between the COMT Val allele and sensitivity for psychosis and 
cognitive effects of THC has been found in individuals with psychosis, as well as their 
relatives (Henquet et al., 2009; Henquet et al., 2006). This is further reinforced by evidence 
that shows different residual and long-term effects of cannabis in psychosis patients versus 
healthy individuals. While the residual and long-term effects of cannabis in using controls 
generally revert to near-normal functioning, they ultimately cognitively underperform 
compared to healthy cannabis-naïve individuals. On the other hand, patients with a history 
of cannabis (but then abstain) demonstrate superior cognition compared to their cannabis-
naïve peers.    
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Summary and Hypothesis 
 Undoubtedly, previous research has indicated that a history of cannabis use in 
schizophrenia patients correlates with better, and in some cases, normal, neurocognition 
compared to their drug-naïve peers. On the other hand, concurrent drug (i.e. cannabis) use 
in either older schizophrenia patients or otherwise healthy individuals has shown cognitive 
deficiencies that transcend psychosis diagnoses. This thesis aims to investigate the theory 
of an alternate pathway to schizophrenia that is mediated by adolescent cannabis use. As 
previous research indicates that patients with a history of cannabis use (who later 
demonstrate better neurocognition) represent a subgroup of patients who may be 
cognitively spared, it is hypothesized that young people with psychosis who concurrently 
use cannabis will exhibit cognition no worse than young people with no history of drug 
use. Ideally this subgroup of patients would not have developed psychosis without the 
environmental trigger of cannabis, and so are not as neurologically impaired as patients 
who develop psychosis regardless of external factors. However, it is also hypothesized that 
after this specific ‘window of vulnerability’, patients who continue to engage in cannabis 
use will begin to display cognitive deficits as their drug use further progresses their illness.   
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Chapter 2 
2. The neurocognitive profiles of psychosis patients with 
cannabis use. 
2.1 Study 1: Meta-analysis of neurocognition in comorbid cannabis-using 
patients.  
 This study has been published in Journal of Psychiatric Research, 2018; 99: 22-
32, Title: Meta-analysis of neurocognition in young psychosis patients with current 
cannabis use. 
2.2 Introduction 
Cannabis remains the most prevalent illicit drug used by individuals with 
schizophrenia-spectrum disorders (Amminger et al., 2006; Koskinen, Löhönen, Koponen, 
Isohanni, & Miettunen, 2010; Smucny, Stevens, & Tregellas, 2014), and current chronic 
use has been shown to significantly worsen positive psychotic symptoms in patients 
(Dubertret, Bidard, Adés, & Gorwood, 2006; Talamo et al., 2006). Counterintuitively, 
meta-analyses and systematic reviews suggest that cognitive functioning in chronic 
schizophrenia patients with a history of, but not current, cannabis use (CANN±) is superior 
to that of their peers who have never used cannabis (CANN-) (Løberg & Hugdahl, 2009; 
Yücel et al., 2012). This suggests that there may be different phenotypes among older 
individuals with chronic psychotic disorders. However, relatively little is known about the 
cognitive profiles in the context of cannabis use in younger individuals with early 
psychosis. Prevalence of psychoses in pre-pubertal children is relatively rare (Thomsen, 
1996), although the incidence of first episode psychosis (FEP) rapidly increases after the 
age of 15 years (Amminger et al., 2006; Gillberg et al., 1986; Hare et al., 2010) with the 
highest rate of a first episode between the ages of 15 and 24 years (Amminger et al., 2006; 
Archie et al., 2007). Young people, aged 12–24 years, represent an important population to 
study psychotic disorders as such individuals represent a subgroup of patients less likely to 
be exposed to critical environmental factors such as chronic use of antipsychotic 
medication (Epstein et al., 2014). There is also evidence that the corpus callosum, the 
highest order, latest maturing network of the brain, continues to grow until the middle 20's 
(i.e. 25.45 years) (Pujol et al., 1993). This, as well as synaptic pruning, which continues 
until the mid-20's, suggests full brain development is incomplete until around 25 years of 
age (Andersen, 2003). Young people are also at a great risk of substance abuse, particularly 
those for whom the age of onset of drug use (alcohol and cannabis, in particular) occurs 
prior to around 15 years of age (Archie et al., 2007; Palmer et al., 2009; Wells et al., 2009). 
Archie et al. (2007) stratified FEP subjects, between 15 and 50 years, into age ranges and 
found that those between the ages of 18–24 years accounted for the largest faction (i.e. 
45%) of patients engaged in concurrent drug use (Archie et al., 2007). It would appear both 
psychotic episodes and substance use during a time when the brain has not fully developed 
could have detrimental effects for patients in the long-term, and cognition and 
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symptomatology during this formidable time needs to be further investigated. Thus, in 
terms of evaluating the potential cognitive dissimilarities associated with and without 
concurrent cannabis use in psychotic disorders a focus on young individuals is highly 
warranted.  
Crean et al.’s extensive review demonstrates the various effects of acute (i.e. 0–6 h 
after use), residual (7 h–20 days after use), and long-term (at least 21 days since use) effects 
of cannabis on neuropsychological functions in healthy populations (Broyd et al., 2016; 
Crean et al., 2011; Curran et al., 2016; Ranganathan & D'Souza, 2006). Acute effects of 
cannabis tend to show the greatest degree of dysfunction, with subjects demonstrating 
impairment across attention, decision making, impulsivity and working memory. Both 
residual and long-term effects appear to largely revert to near-normal functioning, 
specifically in attention, impulsivity and working memory, with a greater period of 
abstinence showing the most advanced improvement in cognition. Theoretically, cannabis 
using patients with a psychotic disorder would be expected to perform worse than their 
non-using counterparts across several cognitive domains, in keeping with studies in healthy 
individuals; whereby poorer cognitive performance in those who are either CANN+ or 
CANN± is most pronounced in tests of executive functioning and processing speed (Meier 
et al., 2012). In contrast, there is evidence that chronic schizophrenia patients who have a 
history of cannabis use (CANN±) outperform their CANN- peers (with schizophrenia) in 
general intelligence, attention, working memory, executive abilities and visuo-spatial 
abilities (Bugra et al., 2013; Jockers-Scherübl et al., 2007; Rabin et al., 2011; Yücel et al., 
2012). Following this logic, one might assume that younger individuals with psychotic 
disorders (e.g. FEP) who use cannabis, but abstain later, will demonstrate improved 
cognitive functioning compared to their peers who never used cannabis. Given this, it is 
possible that the cannabis using patients' psychoses stem from an inherent gene-
environment interaction partially owing to their early onset of cannabis use. Such a 
subgroup of patients may be diagnosed with psychosis, but may also have an atypical 
neurocognitive profile. This reflects Pearlson's review examining significant clinical 
overlap of psychoses and schizophrenia-spectrum disorders (Pearlson, 2015). Furthermore, 
there is evidence such as that provided by the Bipolar-Schizophrenia Network on 
Intermediate Phenotypes (B-SNIP) study, showing that there are clusters of individuals 
with shared biological features (known as ‘bio-types’) despite there being a commingling 
of their traditional clinical phenotype (i.e. schizophrenia or affective psychoses disorders) 
(Hill et al., 2013; Tamminga et al., 2014). Importantly, one of the three biotypes identified 
appears to be associated with higher cannabis use, better cognition, and lower percentage 
of affected relatives (Tamminga et al., 2017). This theory is supported by evidence, which 
shows that chronic schizophrenia patients with CANN± who first began using cannabis 
before the age of 17 years exhibit some superior cognitive functioning compared to patients 
with later (i.e. after 16 years of age) cannabis-use onset (Hanna, Shalvoy, et al., 2016; 
Jockers-Scherübl et al., 2007; Yücel et al., 2012).  
Yücel et al.s' meta-analysis investigated the effect of past cannabis use, typically 
prior to psychosis onset, on neuropsychological performance of older adults (i.e. mean age 
of patients was above 27 years) with a diagnosis of schizophrenia (Yücel et al., 2012). 
CANN± outperformed patients with no history of use (CANN-) in tests of global cognition, 
 20 
processing speed, visual memory, planning, and working memory. However, they also 
found that patients who currently use cannabis (CANN+) did not demonstrate superior 
cognitive performance across a range of measures. Although, these groups differed 
significantly in one cognitive domain: the CANN+ showed worse performance in tests of 
verbal memory. Similarly, a separate study utilized biological radioimmunoassay testing 
rather than drug-use questionnaires to measure current drug use in schizophrenia patients, 
and found no significant cognitive differences between current cannabis-using patients and 
their non-using counterparts (Bahorik, Newhill, & Eack, 2014). However, there are several 
factors that may affect cognitive results, including frequency, dosage, and time since last 
cannabis intake. D'Souza et al. found evidence of dose-specific effects of THC on the 
cognition of schizophrenia patients (D’Souza et al., 2005). They demonstrated temporarily 
increased learning and recall deficits after 2.5 mg or 5 mg of intravenous THC, compared 
to 0 mg, with patients in the 5mg group showing a pattern of worse cognitive performance 
compared to 2.5 mg.  
On the surface, a history of moderate, (potentially regular) lifetime use of cannabis 
followed (importantly) by a period of abstinence in psychosis patients reveals a ‘superior’ 
cognitive profile compared to those with a psychotic disorder who never used or those who 
have continued to use (i.e. current use in older, more chronic stages of schizophrenia). 
Intriguingly, it appears that when cannabis use begins during adolescence, before the age 
of 17, those who later abstain (i.e. CANN±) demonstrate better neurocognitive performance 
than their CANN± peers who began using after 17 years. However only a handful of studies 
report any evidence of cognitive dysfunction in cannabis-using adolescents diagnosed with 
psychosis. Furthermore, cannabis use in the neurodevelopmental period of adolescence has 
been shown to confer a range of cognitive, social, and psychological harms (Di Forti et al., 
2014; Henquet et al., 2005; Mackie et al., 2013; Meier et al., 2012; Meier, Hill, Small, & 
Luthar, 2015; Scholes-Balog, Hemphill, Evans-Whipp, Toumbourou, & Patton, 2016; 
Szoke et al., 2014; Tien & Anthony, 1990). In fact, Henquet et al.  found that any cannabis 
use exacerbates psychotic symptoms in young people, parti- cularly in those who have a 
predisposition for psychosis (Henquet et al., 2005).  
Given the above-mentioned findings, the aim of the current study was to 
systematically review the potential effects of cannabis use on cognition in adolescent and 
young adult patients with psychosis. From previous evidence, we expected cannabis users 
to show significant deficits across a range of neurocognitive tests, as compared to non-
using patients. However, young cannabis-using patients were expected to demonstrate 
superior neurocognitive performance compared to older CANN+ and CANN-, or young 
CANN-.  
2.3 Methods 
2.3.1 Search strategy and selection criteria  
Studies were identified through extensive online database searches, including 
PubMed, Medline, and Psycinfo. Searches included keywords involving psychosis (i.e. 
schizophrenia, schizophreniform, psychosis, schizoaffective, schizo*, FEP, first, episode), 
cannabis (i.e. cannabis, marijuana, THC, tetrahydrocannabinol), and cognition (i.e. 
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neuropsycho*, neurocognit*, cogniti*), and were limited to English-language articles with 
human participants. All articles up to October 2016 (i.e. the month the searches were 
conducted) were considered for analysis. A secondary search was conducted by reviewing 
the reference lists of relevant review and meta-analytic papers.  
The inclusion criteria were: (1) diagnosis of a psychotic disorder according to DSM 
(i.e. Schizophrenia Spectrum and Other Psychotic Disorders) or ICD (i.e. Schizophrenia 
Spectrum and Other Primary Psychotic Disorders) criteria; (2) studies had to compare a 
psychotic (or schizophrenia spectrum disorder) cannabis-using group to an appropriate 
clinical control group (i.e. psychotic nonusers); (3) cannabis was the predominate substance 
used by patients, as stated by the authors in the methodology; (4) the assessment of 
traditional neuropsychological functions using valid and reliable tests, used routinely in 
clinical practice (Strauss, Sherman, & Spreen, 2006); and (5) sufficient statistical data were 
reported for transformation into effect sizes (ES), or the relevant data were available from 
the original researchers.  
Studies were excluded if they included cases who: (1) were diagnosed with a 
substance/medication-induced psychotic disorder, or were intoxicated at time of testing; or 
(2) investigated individual components of cannabis (e.g. tetrahydrocannabinol [THC] or 
cannabidiol [CBD] on their own); or (3) investigated synthetic cannabis. Only studies with 
the largest sample were included in the instance of overlapping samples.  
As shown in Fig. 1, 308 titles and abstracts were initially identified, but only 44 
studies assessed both cannabis use and cognition in psychotic patients. Thirty of these 
studies were excluded because: (1) the patient sample had irrelevant diagnoses (Buchy et 
al., 2015; Hollis et al., 2008; Korver et al., 2010; van Tricht et al., 2013), (2) the study 
included no relevant neuropsychological tests (Bourque et al., 2013), (3) they lacked 
patients involved in current cannabis use (Cunha et al., 2013; de la Serna et al., 2010; 
DeRosse, Kaplan, Burdick, Lencz, & Malhotra, 2010; Epstein et al., 2014; Hanna, Shalvoy, 
et al., 2016; Jockers-Scherübl et al., 2007; Krzysztof et al., 2012; Leeson, Harrison, Ron, 
Barnes, & Joyce, 2012; Løberg et al., 2012; Mata et al., 2008; Moreno-Granados, Ferrín, 
Salcedo-Marín, & Ruiz-Veguilla, 2014; Power et al., 2015; Rentzsch et al., 2016; Schnell 
et al., 2009a; Sevy et al., 2007; Stirling, Lewis, Hopkins, & White, 2005a; Wobrock et al., 
2007; Yücel et al., 2012), (4) cannabis was not the predominate substance abused (I. 
Harrison et al., 2008), and (5) there was insufficient data and we were unable to obtain data 
from the authors (Arnold et al., 2015; Bahorik et al., 2014; Løberg & Hugdahl, 2009; Meijer 
et al., 2012; Pencer & Addington, 2003; Potvin et al., 2005).  
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Figure 2-1: Flow chart of the studies considered and selected for review. 
All studies in the meta-analysis included a psychotic patient sample who were 
current cannabis users, defined as at least weekly cannabis use in the past 6 months. In 4 
of the 14 studies, the patients were considered a young sample (mean age is less than 25 
years), while the other 10 studies comprised of adult patients (mean age is older than 24 
years). Overall, our meta-analysis included 14 studies involving 1430 patients with 
psychosis, with (N = 529) and without (N = 901) comorbid cannabis use. 
2.3.2 Meta-analytic procedure  
All meta-analytic procedures were conducted using Comprehensive Meta-Analysis 
Version 2.0 (Borenstein, 2005). One author (S.B.) extracted patients' demographic data and 
cognitive test results from the articles. In cases where raw data was not available, the 
authors were contacted and demographic data and/or test results re- quested. Effect size 
(Hedges' g) was calculated for each cognitive do- main. In cases where a study used two 
cognitive tests for one domain, the tests were grouped together, and the average ES was 
calculated. A more positive ES indicated better performance for CANN+ than CANN-, and 
in keeping with the literature, the size of the ES was interpreted according to Hedge's g (0.2 
= small; 0.5 = medium; 0.8 = large) (Hedges & Olkin, 1985; Lee, Hermens, Porter, & 
Redoblado-Hodge, 2012). A random effects model was used for meta-regression (i.e. 
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unrestricted-maximum likelihood) and subgroup analyses (i.e. method of moments), with 
a significance level set at p < .10 (Zeggini & Ioannidis, 2009). As described in Table 1, 
cognitive domains included were pre- morbid IQ, current IQ, processing speed, cognitive 
flexibility, sustained attention, verbal learning, verbal memory, verbal working memory, 
conceptual set-shifting, motor inhibition, and verbal fluency. In longitudinal studies, only 
cross-sectional neuropsychological results were used to circumvent practice effects 
(McCleery, Addington, & Addington, 2006; Sánchez-Torres et al., 2013; Wobrock et al., 
2013). Heterogeneity between studies was tested using the Q-test, and publication bias was 
assessed using Egger's test (Egger, Smith, Schneider, & Minder, 1997; Higgins, Thompson, 
Deeks, & Altman, 2003). Subsequent tests of Rosenthal's Fail-Safe N, and Duval and 
Tweedie's Trim and Fill method were carried out to determine the number of studies 
required to establish no publication bias (Duval & Tweedie, 2000a, 2000b; Rosenthal, 
1979).  
Table 2-1: Cognitive domains and the corresponding neuropsychological tests included in each 
analysis. 
 
2.3.3 Moderator analyses  
Predictors of between-study variability in ES were examined using meta-
regression (for continuous predictors) and subgroup analyses (Qbet, for categorical 
predictors). The predictors were included if a sufficient number of studies had reported 
these variables (i.e. no more than one study missing per cognitive domain). These were 
grouped as either:  
1) Demographic predictors included ‘age’ and ‘sex’. A number of studies have 
indicated the significance of age in confounding the differences between CANN+ and 
CANN- (Ochoa, Usall, Cobo, Labad, & Kulkarni, 2012; Potvin et al., 2008). As we are 
also interested in neuropsychological differences between young and adult patients, 
regressions for age were performed for each cognitive domain. Similarly, gender 
differences are well-recognized among both cannabis-users, and psychosis patients, where 
cannabis-users more often tend to be men (Ochoa et al., 2012; Spauwen, Krabbendam, 
Lieb, Wittchen, & van Os, 2003).  
2) Diagnostic predictors included patient diagnosis (‘psychotic disorder’ or 
‘schizophrenia-spectrum disorder’). In the present study, we classified psychosis and 
schizophrenia as two distinct diagnoses (A.P.A., 2013). Although psychosis is a core 
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symptom of schizophrenia, patients with a diagnosis of psychosis alone do not experience 
the full spectrum of a psychotic illness. Schizophrenia patients also display greater 
cognitive deficits than patients with first- episode psychosis alone (Yücel et al., 2012), the 
latter of which is a more heterogeneous group comprising substance use disorders and 
affective disorders with psychotic features.  
2.4 Results  
A total of 14 studies, published up to October 2016, met inclusion criteria and were 
incorporated into the meta-analysis (see Table 2). Six of the studies included patients 
diagnosed with solely psychotic disorders (Bugra et al., 2013; de la Serna et al., 2010; 
González-Pinto et al., 2016; Lev-Ran, Segev, Braw, & Levkovitz, 2012; McCleery et al., 
2006; Núñez et al., 2016), while the remaining eight focused on patients diagnosed with 
narrower schizophrenia-spectrum disorders (Coulston et al., 2007; Ferraro et al., 2013; 
Fischer et al., 2015; Rabin, Zakzanis, Daskalakis, & George, 2013; P.A. Ringen et al., 2010; 
Sánchez-Torres et al., 2013; Scholes & Martin-Iverson, 2010; Wobrock et al., 2013). Four 
studies originated in Spain, two each from Australia, and Canada, and one each from the 
United Kingdom, Switzerland, Norway, the United States, Israel, and Germany. Sample 
sizes varied from 26 to 319. There was a total of 529 CANN+ cases, compared with a total 
of 901 CANN- controls. The proportion of female participants was a weighted average of 
17.4% for CANN+ and 39% for CANN-. The mean age was a weighted average of 25.0 
years for CANN+ and 27.9 years for CANN-. Five studies explicitly defined cannabis users 
as having cannabis dependence, whereas the remaining nine studies included users with 
any sort of cannabis use over at least the previous month.  
The effect sizes and related statistics of differences in performance between CANN+ 
and CANN- are presented in Table 3. Effect sizes were in the small to medium range 
(Hedges g = 0.13–0.55), with the exception of verbal working memory (Hedges g = 0.76). 
Most ES suggest poorer cognitive performance in CANN+ compared to CANN-. Table 4 
presents the moderator analyses for predictors of heterogeneity. A more positive ES 
indicates better performance in CANN+ than CANN- (see Supplementary Figures for 
forest plots of each cognitive domain).  
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Table 2-2: Summary of key characteristics of studies. 
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2.4.1 Current and premorbid IQ  
All seven studies that incorporated tests of premorbid IQ reported poorer 
performance for CANN+, with the overall ES significantly in favour of CANN- (g = 
−0.40). Similarly, the six studies that measured current IQ also reported significant deficits 
in CANN+ subjects (g = −0.17). There was no significant heterogeneity in premorbid and 
current IQ across studies. A more equal proportion of sexes (i.e. increased female 
representation) was predictive of greater superiority in current IQ in CANN+ (Z = 2.03).  
 
Table 2-3: Number of studies (k), pooled sample size (N), pooled ES (Hedge's g), homogeneity (Q, 
I, tau (Smucny et al., 2014)), and publication bias. 
 
 
Table 2-4: Moderator analyses to determine predictors of heterogeneity. 
 
 
2.4.2 Processing speed  
Ten studies reported tests of processing speed, demonstrating no effects between 
cannabis groups. A more equal sex distribution was indicative of better performance in 
CANN+ (Z = 1.83). Both in- creasing age and a diagnosis of schizophrenia were predictive 
of poorer performance in tests of processing speed for CANN+ (Z = −1.87; Qbet = 7.22).  
 
2.4.3 Cognitive flexibility  
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Eight studies included tests of cognitive flexibility, with only one test used in all 
articles (i.e. TMT-B). ES were not significant. There was a high level of heterogeneity 
among studies, but none of the moderators were predictive for this result.  
 
2.4.4 Sustained attention  
The nine articles that reported tests of sustained attention demonstrated non-
significant ES. ES across studies were significantly heterogeneous. Both increasing age 
and a diagnosis of schizophrenia resulted in poorer performance for CANN+ (Z = −2.61; 
Qbet = 5.29).  
 
2.4.5 Verbal learning  
CANN+ showed significant deficits in tests of verbal learning (g = −0.39). ES 
across studies were significantly heterogeneous. Increasing age was predictive of superior 
performance in tests of verbal learning for CANN+ (Z = 1.84).  
 
2.4.6 Verbal memory  
ES for verbal memory tests was non-significant, and heterogeneous across studies. 
Increasing age and diagnosis of schizophrenia were predictive of poorer performance in 
CANN+ (Z = −1.90; Qbet = 5.30).  
 
2.4.7 Verbal working memory  
Six studies incorporated tests of (verbal) working memory, and show significant 
difference between cannabis groups (g = −0.761). ES across studies was significantly 
heterogeneous. A more equal sex distribution was indicative of poorer performance in 
CANN+ (Z = −2.28).  
 
2.4.8 Conceptual set-shifting  
Eight studies reported results from Wisconsin Card Sorting Test (WCST), which 
measures conceptual set-shifting. CANN+ performed significantly better than CANN- (g 
= 0.318), with high heterogeneity across studies. None of the moderators were predictive 
of this result.  
 
2.4.9 Motor inhibition  
Motor inhibition was significantly poorer in CANN+ (g = −0.189). Studies were 
not heterogeneous.  
 
2.4.10 Verbal fluency  
Tests of verbal fluency were non-significant between groups. Studies were 
significantly heterogeneous. Both a more equal sex distribution and decreasing age result 
in poorer performance for CANN+ (Z = −1.80; Z = 2.36).  
 
2.4.11 Publication bias  
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Of the neuropsychological domains that differentiated CANN+ from CANN-, there 
was no evidence to suggest that these domains were influenced by publication bias (p > 
.10) (See Supplementary Materials for funnel plots).  
 
2.5 Discussion  
To our knowledge, this was the first meta-analysis to systematically investigate the 
neurocognitive profile of psychotic disorders in young people who use cannabis. As 
expected, never-using patients (CANN-) outperformed current cannabis-using cases 
(CANN+) across tests of premorbid and current IQ, verbal learning, verbal working 
memory, and motor inhibition. This is consistent with previous studies showing that 
patients with current or recent cannabis use display cognitive deficits when compared to 
those with a lifetime history of past cannabis use, as well as those with no history of 
cannabis use (Løberg & Hugdahl, 2009). Unexpectedly, CANN+ in the present study 
performed better than CANN- in conceptual set-shifting tasks (i.e. Wisconsin Card-Sorting 
Task), an outcome that contrasts with previous findings (Scholes & Martin-Iverson, 2010). 
However, most ES in these analyses have appeared to show a relatively small to medium 
degree (i.e. 0.2 to 0.5 ES range) of dysfunction in cannabis-users (Hedges & Olkin, 1985; 
Lee et al., 2014). This is unsurprising, as a number of epidemiological studies have instead 
reported non-significant to small cognitive differences between CANN+ and their non-
cannabis using peers. The largest ES observed in this study was for verbal working 
memory, whereby CANN+ performed worse than CANN-. Yücel et al. also found that non-
using patient groups performed better in verbal memory than recent users (Yücel et al., 
2012). Similarly, Schoeler et al.’s meta-analysis investigating memory function in older 
psychosis patients (i.e. mean age of patients was above 27 years) with CANN± found users 
who abstained less than 10 days performed poorly in memory tasks compared to prolonged-
abstinent psychosis patients. Thus, consistent with these previous meta-analyses of older 
adult patients (i.e. typically after the age of 25), our findings indicate that there are 
significant cognitive deficits in the recent cannabis-using patient groups, despite age 
(Schoeler, Kambeitz, Behlke, Murray, & Bhattacharyya, 2016; Yücel et al., 2012). In other 
words, it appears that cannabis use at any age is associated with (an overall tendency for) 
poorer cognitive capacity.  
Thus, the findings of this study provide support for current cannabis-users with 
psychosis having inferior cognitive abilities. Consistent with previous papers, cannabis use 
was associated with a younger age and male gender (Dixon, 1999; B. Green, Young, & 
Kavanagh, 2005; Linszen et al., 1994; Malone, Hill, & Rubino, 2010; Mueser, Yarnold, & 
Bellack, 1992; H. Myles, Myles, & Large, 2016; Veen et al., 2004; Winklbaur, Ebner, 
Sachs, Thau, & Fischer, 2006). Several studies indicate poorer performance of CANN+ 
groups in immediate verbal learning, and working memory (Coulston et al., 2007; Cunha 
et al., 2013; de la Serna et al., 2010; González-Pinto et al., 2016; McCleery et al., 2006; 
Meijer et al., 2012; P.A. Ringen et al., 2010; Yücel et al., 2012). Decreased memory 
capability is however a well-known effect of recent cannabis use, with evidence showing 
any more than one cannabis joint per week was associated with poorer verbal working 
memory capacity in healthy individuals (Chait & Perry, 1994; Fant, Heishman, Bunker, & 
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Pickworth, 1998; Heishman, Huestis, Henningfield, & Cone, 1990). CANN+ also 
demonstrated motor inhibition deficits in the present study, supporting the notion that 
individuals, whether diagnosed with a psychotic disorder or otherwise healthy, perform 
significantly worse than non-users in tests of cognitive inhibition (Prashad & Filbey, 2017; 
Wrege et al., 2014). Functional magnetic resonance imaging (fMRI) has shown that 
individuals under the influence of delta-9-tetrahydrocannabinol (THC), the main 
psychoactive component in cannabis, attenuates activation in the right inferior frontal and 
anterior cingulate gyrus during the Go/No-Go task. Activation in these regions during the 
response-inhibition task is thus likely responsible for impairments in the inhibitory control 
of thoughts and emotions, as well as motor responses, as often viewed symptomatologically 
in schizophrenia (Bhattacharyya et al., 2015; Borgwardt et al., 2008).  
There is evidence that CANN+ present with a higher premorbid IQ (Ferraro et al., 
2013; Løberg & Hugdahl, 2009; Yücel et al., 2012), which contrasts with findings in the 
present study. Ferraro et al. found a significant increase in premorbid and current IQ in 
patients who had any lifetime experience with cannabis, but not in CANN+ (Ferraro et al., 
2013). Interestingly, they also found CANN+ who engaged in their use socially tended to 
have higher premorbid IQ than patients who chose to use cannabis alone. Despite evidence 
demonstrating superior premorbid IQ in patients engaged in cannabis use, several studies 
have instead found no differences between CANN+ and CANN- (Bugra et al., 2013; Núñez 
et al., 2016; Scholes & Martin-Iverson, 2010; Waterreus, Badcock, Di Prinzio, Martin-
Iverson, & Morgan, 2017). Scholes and Martin-Iverson found no significant cognitive 
differences between CANN+ and CANN- in older (i.e. above 24 years of age) 
schizophrenia patients, with the exception of CANN+ instead showing deficits in 
conceptual set-shifting (i.e. Wisconsin Card Sorting Task) when compared to CANN- 
(Scholes & Martin-Iverson, 2010). On the other hand, Jockers-Scherübl and colleagues 
claim there are no differences between CANN± and CANN- in conceptual set-shifting 
(Jockers-Scherübl et al., 2007), indicating the superior adaptive ability of CANN+ in the 
current study does not transcend all patient ages and varying recency of cannabis use. A 
recent cross-sectional study has also concluded that there are no significant differences 
present between CANN+ and CANN- in domains of premorbid and current IQ, attention, 
processing speed, and memory (Waterreus et al., 2017). Clearly several confounders 
influence the subsequent outcomes of neurocognitive testing in these patient groups. 
Unfortunately, there are very few studies available that examine the neurocognition in 
current cannabis-using psychosis patients. While the literature in this area is already 
extremely limited, there are only a handful of reports that look at cannabis' influence on 
young people with psychosis (i.e. under 25 years). As one of the most paramount factors in 
this study is the impact of patients' age, we performed meta-regressions to view the 
influence of age on cognitive performance.  
Onset of cannabis use tends to begin during the adolescent years, with initial use 
on average occurring at 15 years of age (Archie et al., 2007; Palmer et al., 2009; Wells et 
al., 2009). This is also the age many early-onset psychosis patients, particularly males, 
experience their first episode. In the present study, young (i.e. below 25 years of age) 
CANN+ performed significantly better in processing speed, sustained attention, and verbal 
memory than older (i.e. above 24 years) CANN+ patients. Previous studies have suggested 
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that in some cases for older CANN+ patients, cumulative exposure to cannabis over several 
years may contribute to poorer results in cognitive tests compared to younger patients. 
Young patients are also more likely to have had less treatment exposure (e.g. antipsychotic 
medications) over their lifetimes (Bossong & Niesink, 2010; Kolb & Gibb, 2011). On the 
other hand, young CANN+ showed greater deficiencies in verbal learning and verbal 
fluency. As previously noted, cannabis effectively influences the user's memory and 
learning abilities. In younger patients, this would be more influential given the critical brain 
maturation processes occurring in the 16–25 years age period; further compounded by the 
early age of cannabis use onset (Bagot, Milin, & Kaminer, 2015). These results generally 
fall in line with Løberg and Hugdahl's reanalysis of previous data, in which CANN± 
outperformed CANN- in a number of cognitive domains, including learning and memory, 
attention and working memory, executive functions, and psychomotor speed (Løberg & 
Hugdahl, 2009). They also showed CANN+, who were admitted to a psychiatric emergency 
ward, demonstrated a significantly larger improvement in their cognitive performance only 
three months after admission, compared to their non-using counterparts. In fact, evidence 
suggests cannabis onset preceding 17 years of age leads better cognitive outcomes for 
CANN± later in life (i.e. within 2–10 years after cannabis abstinence) (Helle et al., 2014; 
Jockers-Scherübl et al., 2007; Løberg & Hugdahl, 2009; Yücel et al., 2012). One 
explanation regarding this paradoxical phenomenon is that the patients with such early 
onset of cannabis use instead triggers their own illness, and represent a subgroup of 
psychoses patients with high genetic loading, likely due to a specific gene poly-morphism 
in this cohort (Malone et al., 2010; Tost, Alam, & Meyer-Lindenberg, 2010). Caspi and 
colleagues conducted a longitudinal study of 800 adolescent cannabis onset users; they 
found that a functional polymorphism in the catechol-O-methyltransferase (COMT) gene 
moderates the influence of adolescent cannabis use on developing adult psychosis (Caspi 
et al., 2005). However, this study has not been replicated, and the evidence on whether such 
polymorphisms modulate the risk for psychosis associated with exposure to cannabis is 
mixed with some (Caspi et al., 2005) but not other (Henquet et al., 2006; Tunbridge et al., 
2015; Zammit et al., 2007) studies showing an effect. In some cases, cannabis use, 
combined with polymorphisms in the COMT gene appeared to not only increase the risk 
of schizophreniform disorder, but also results in younger age of psychosis onset (Caspi et 
al., 2005; Pelayo-Terán et al., 2010). On the other hand, there is also evidence of no 
cognitive or affective differences mediated by the COMT gene with cannabis use 
(Kantrowitz et al., 2009; Zammit et al., 2007). This indicates the observed gene-
environment interaction may be limited to a sensitive period of brain development in 
adolescence.  
The proportion of females in each cannabis group played a significant function in 
the subsequent performance of the psychoses groups. Males are three times more likely 
than females to be diagnosed with a psychotic disorder (Iacono & Beiser, 1992) 
Furthermore, several studies have found substance use by men (typically with cannabis and 
alcohol) well outnumber women, both in cases with and without psychotic disorders 
(Ochoa et al., 2012; Schepis et al., 2011). Our results parallel the underrepresentation of 
females in psychosis populations, as males outnumbered females in all studies, specifically 
in CANN+. Equal sex distributions were predictive of better performance in current IQ and 
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processing speed for CANN+, whereas more equal distributions implied deficiencies in 
verbal working memory and verbal fluency. Our findings contrast Rabin et al., who found 
no cognitive differences between male schizophrenia CANN+ and CANN- patients (Rabin 
et al., 2013). In addition to age and sex, it may be important to consider diagnostic subtypes 
(e.g. affective-versus schizophrenia-spectrum) as a key factor in our understanding of 
concurrent psychosis and cannabis use. Løberg et al. support previous hypotheses in their 
detailed literature review that pre-illness cannabis use confers a greater risk for affective 
psychosis, which appears to have a better cognitive prognosis than cannabis-using 
schizophrenia-spectrum patients (Bora et al., 2009; Krabbendam, Arts, van Os, & Aleman, 
2005; Løberg et al., 2014; Manrique-Garcia et al., 2012). Although several studies indicate 
only small effect sizes between affective psychosis and schizophrenia diagnoses, 
schizophrenia patients consistently perform worse than affective psychosis patients in tests 
of crystallized knowledge, verbal skills, information processing speed, and verbal memory 
(Barch, 2009; Depp et al., 2007; Hill et al., 2013; Krabbendam et al., 2005; Schretlen et al., 
2007). In fact we found CANN+ (affective-) outperformed CANN+ (schizophrenia-
spectrum) in tests of processing speed, sustained attention and verbal memory. 
Schizophrenia-spectrum CANN+ showed no cognitive lead over affective- CANN+. To 
our knowledge, there are no present studies directly investigating cognitive differences 
between affective- and non-affective psychoses, however neuroimaging studies suggest 
atypical dopamine synthesis in the striatum may account for the induction of psychosis in 
a different mechanism typically seen in schizophrenia (Batalla et al., 2014; Tost et al., 
2010).  
Notably, the dopaminergic and cannabinoid systems in the brain develop early on 
in young adulthood. A number of brain regions that are implicated in psychosis and other 
schizophrenia-spectrum disorders, are also densely populated with cannabinoid receptors, 
and are as such, heavily affected by THC in cannabis (D’Souza et al., 2005). Several 
abnormalities of the endogenous cannabinoid system in pa- tients with schizophrenia, 
occurring before the use of cannabis, are apparent. These include increased levels of 
cannabinoids in both the frontal cortex and cerebral spinal fluids (Dean, Sundram, 
Bradbury, Scarr, & Copolov, 2001; Leweke, Giuffrida, Wurster, Emrich, & Piomelli, 
1999). It is therefore possible that changes to this atypical endocannabinoid system, by 
external cannabinoids, could be involved in the pathology of psychotic disorders. The 
findings presented here support the notion that there are distinct cognitive profiles 
according to the patients' age as well as the pattern of their cannabis use. While increased 
cumulative exposure to cannabis may account for some of these results, it is also possible 
that the developing brain in young people, especially with psychosis, are more vulnerable 
to the effects of cannabis than a matured brain. It would be important to understand the 
initial effects of cannabis on the brain of a psychosis patient, specifically that of a young 
person, to better understand the prognostic implications of concurrent cannabis use in 
psychoses, and recognise how to treat young adults and adults who currently engage, and 
have a lifetime history, in cannabis use.  
There are some limitations in our study that should be considered. First, there are 
a few key factors that were not investigated in this study. Frequency and dosage, which 
was addressed in only three of the present studies, are notable influences that impact the 
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effect of cannabis on patients. Nunez and colleagues demonstrated that heavy cannabis 
users (i.e. more than three cannabis joints per day) showed significant cognitive 
deficiencies in tasks of verbal learning, attention and processing speed when compared to 
medium users (i.e. less than three cannabis joints per day) and non-using patients (Núñez 
et al., 2016). Similarly, duration of cannabis use varies among the studies analysed. The 
findings in the present study should be taken with some caution, given the diverse range of 
duration of cannabis use among patients (i.e. 6 months to 2+ years). Interestingly, the 
majority of studies found that a higher frequency of cannabis use predicts better 
performance in cognition, specifically attention and working memory (Coulston et al., 
2007; Schnell et al., 2009a).  
Second, different methodologies across studies prove to be a limitation for reviews 
and meta-analyses. As the included studies all measured separate outcomes, we were 
unable to compare several clinical and demographic characteristics of the patient groups. 
Several studies have indicated the significance of general psychopathy sub-scores and 
symptomology on prognosis, progression and performance on cognition (Grech, van Os, 
Jones, Lewis, & Murray, 2005; Helle et al., 2014; Linszen et al., 1994; Meijer et al., 2012; 
Power et al., 2015). The magnitude of cognitive dysfunction may also be dependent on the 
patient's diagnosis, or sub-group of psychotic disorder (i.e. affective psychosis or 
schizophrenia-spectrum disorder). Schizophrenia-spectrum patients appear to be more 
cognitively compromised than those with affective psychosis or FEP alone (Reichenberg 
et al., 2009), however all psychotic disorders consistently underperform in tests of memory, 
executive functions, attention, and processing speed (Gooding & Tallent, 2002; Heinrichs 
et al., 2008; Hill, Keshavan, Thase, & Sweeney, 2004; Hill et al., 2013; Reichenberg et al., 
2009; Tamminga et al., 2014). Future studies must tease out these discrete disorders in 
order to best represent schizophrenia-spectrum, FEP, and affective-psychosis patients, as 
varying heterogeneity between subgroups appears to somewhat effect cognitive outcomes 
of each clinical group (Van Rheenen et al., 2017; Welham, Thomis, & McGrath, 2003). 
Discrepancies between potential and actual performance of patients due to these 
confounding factors may in fact significantly alter results if not matched between patient 
groups. Similarly, comorbid cannabis use and psychoses patients with a family history of 
psychosis suggests better performance in areas of verbal memory, executive function and 
global cognition compared to patients without the family history of illness (González-Pinto 
et al., 2016), further indicating the influence of confounding factors often undisclosed to 
us in this study.  
Third, some studies used in our analyses included patients engaging in other 
comorbid substance abuse, particularly alcohol and cocaine. However studies that 
investigated the effect of alcohol use on cognition of psychosis patients found no 
association (Pencer & Addington, 2003; Potvin et al., 2008; Yücel et al., 2012), instead 
suggesting regular alcohol use leads to greater positive symptoms. Bahorik et al. analysed 
the neurocognitive functioning of schizophrenia patients who currently use cocaine and/or 
methamphetamine and also found no associations between the drugs and cognition 
(Bahorik et al., 2014).  
Fourth, there is evidence that some components of cannabis (e.g. cannabidiol 
[CBD]) might ameliorate psychotic symptoms and improve acute cognition (Morgan & 
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Curran, 2008). On the other hand, different strains of, as well as synthetic, cannabis, which 
was not taken into account in a majority of the studies analysed, may also mediate the drug's 
effect on cognition (Morrison et al., 2009; Radhakrishnan, Wilkinson, & D'Souza, 2014). 
Future studies should consider the effect of varying proportions of THC and CBD in 
different strains of cannabis, as well as the more neurotoxic and harming effects involved 
with synthetic cannabis.  
Unfortunately, the literature on the neurocognitive effects of cannabis use in 
psychosis patients who are under the age of 25 years is exceptionally limited. Although a 
number of studies show evidence to suggest that older CANN± patients (i.e. above 25 
years) possess a superior capability to adapt to changing environments and circumstances, 
which may incorporate social settings (Arnold et al., 2015; Bossong & Niesink, 2010; 
Joyal, Hallé, Lapierre, & Hodgins, 2003; Larsen et al., 2006; Meijer et al., 2012; Potvin et 
al., 2005; P. A. Ringen et al., 2008), to our knowledge there are no reports investigating the 
cognitive effects of lifetime cannabis use in psychosis patients who are under the age of 25 
years. Similarly, despite one prevalent theory that addresses the superior social abilities of 
CANN+ is the social demand required to obtain illicit drugs (Bhattacharyya & McGuire, 
2011; Bossong & Niesink, 2010; Burns, 2013; Løberg & Hugdahl, 2009; Yücel et al., 
2012), only a limited number of studies have actually looked into any potential cognitive 
differences at the time of both psychosis- and cannabis-onset, as often observed in young 
people. In conclusion, our meta-analysis supports previous findings of cognitive 
deficiencies in psychosis patients who currently use cannabis. Most noteworthy is the 
superior performance of young patients who use cannabis, which could suggest a subgroup 
of psychosis patients. While prior research indicates lifetime users outperform non- using 
patients in several neuropsychological tests, our findings indicate young people with both 
an early-onset of cannabis use and FEP may represent a subgroup of patients who develop 
psychosis through an alternative pathway not otherwise observed in traditional psychosis 
patients who aren't involved in drug use. This evidence indicates distinct treatment plans 
for psychosis patients need to be utilized to properly care for, perhaps, differing forms of 
psychosis that arise through varying mechanisms. However, more research needs to be 
conducted into the effects of cannabis use on young psychosis patients to further investigate 
the cognitive changes and differences during the time of both psychosis- and cannabis-
onset. This will facilitate greater understanding of the superior capabilities observed in 
lifetime, but not current, cannabis users, as compared to non-using psychosis patients.  
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Chapter 3 
3. The neurocognitive profile of young psychosis patients 
with current cannabis use. 
3.1 Study 2: The neuropsychological profiles of young psychosis patients 
with and without current cannabis use. 
  This study is under review at Cognitive Neuropsychiatry, Title: The 
neuropsychological profiles of young psychosis patients with and without current cannabis 
use. 
3.2 Introduction 
The neurocognitive and clinical profiles of patients with psychosis have been 
scrutinized in recent years, closely following mounting evidence of the moderating effect 
of history of cannabis use on expression of neurocognitive and symptomatic impairment 
(Frascarelli et al., 2016; González-Pinto et al., 2016; Hanna, Perez, & Ghose, 2016; Mallet, 
Ramoz, Le Strat, Gorwood, & Dubertret, 2017; Murray, Quigley, Quattrone, Englund, & 
Di Forti, 2016; Waterreus et al., 2017; Yücel et al., 2012). Much of the research observing 
neuropsychological consequences of cannabis use on psychosis patients involves lifetime, 
but not current use, and so tend to focus on adult but not adolescent patients. These studies 
generally conclude that patients with previous cannabis use outperform cannabis-naive 
patients in a number of cognitive tests, particularly in tests of working memory and 
executive function (Coulston et al., 2007; Jockers-Scherübl et al., 2007; Potvin et al., 2008; 
Schnell, Koethe, Daumann, & Gouzoulis-Mayfrank, 2009b; Stirling, Lewis, Hopkins, & 
White, 2005b; Wobrock et al., 2007). This peculiar outcome conflicts with studies 
observing cannabis-using, but otherwise healthy participants. The general consensus in 
healthy populations with both current and previous cannabis use is that these participants 
underperform in several tests of cognition compared to non-users, regardless of (long-term) 
abstinence (Bartholomew, Holroyd, & Heffernan, 2010; Fletcher et al., 1996; Pope & 
Yurgelun-Todd, 1996; Solowij, 1988). 
Crean’s review of acute and long-term effects of cannabis on the cognition of healthy 
populations revealed several cognitive impairments in abstinent cannabis-users, 
specifically in attention, working memory, decision-making and motor inhibition (Crean et 
al., 2011). Evidently, psychosis patients and participants from a healthy population 
demonstrate conflicting neuropsychological profiles in those who have lifetime, but not 
current, cannabis use. There is also evidence to suggest that psychosis patients who began 
using cannabis before the age of 17 (but are currently abstinent) exhibit better cognitive 
performance than both psychosis patients who began using after the age of 17 or never at 
all (Jockers-Scherübl et al., 2007; Yücel et al., 2012). Stirling and colleagues similarly 
found that regular cannabis use occurring before psychosis onset predicted spared cognition 
10 years later (Stirling et al., 2005b). They demonstrated that although cannabis-using FEP 
patients were younger and exhibited more positive symptoms at baseline, these cannabis-
using patients, at follow-up 10 years later, actually demonstrated equal or superior 
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neurocognitive profiles compared to their non-cannabis-using counterparts (Stirling et al., 
2005b; Stirling et al., 2003a). These results parallel Hanna and colleagues’ findings of 
variability in adult psychosis patients’ subsequent neurocognition, as moderated by their 
adolescent cannabis use (Hanna, Shalvoy, et al., 2016). While neither adolescent- nor later-
onset of cannabis use predicted any difference in cognition in patients with bipolar-type 
psychosis, patients with both adolescent-onset cannabis use and schizophrenia psychosis 
demonstrated superior cognition compared to other schizophrenia groups (i.e. 
schizophrenia with no cannabis use, and schizophrenia with later [after 18 years] onset of 
cannabis use). Conversely, Scholes and Martin-Iverson demonstrated that although patients 
with schizophrenia expectedly underperformed across all administered cognitive tests 
compared to healthy controls, regardless of cannabis use status, there were no significant 
differences between the two clinical groups (i.e. schizophrenia patients with or without 
current cannabis use) (Scholes & Martin-Iverson, 2010).  
There appears to be emerging evidence of alternative pathophysiological pathways 
to schizophrenia, at least one of which is mediated by cannabis use. Several studies indicate 
spared cognition for patients with lifetime cannabis use after long-term abstinence, 
however few studies actually observe the effects of current cannabis use on patients’ 
cognition. As expected, it appears comorbid adult psychosis patients with current cannabis 
use significantly underperform in a number of cognitive tests, when compared to non-using 
patients, demonstrating similarities between cannabis-using and non-using healthy 
controls. Waterreus and colleagues’ study focusing on adult psychosis patients further 
advanced Hannah and colleagues’ findings by demonstrating cognitive deficits were only 
present in current cannabis-using affective psychosis patients, but not in those diagnosed 
with non-affective psychosis (Waterreus et al., 2017). In fact, our recent meta-analysis of 
1,430 participants across 14 studies (Bogaty, Lee, Hickie, & Hermens, 2018) demonstrates 
the potential effects of current cannabis use on patients’ cognition, with a focus on the 
impact of age. We found that while current users present deficits in several cognitive tests 
compared to patients with no history of cannabis use, age moderated the effect of current 
cannabis use on cognition with greater impairment in most cognitive domains found for 
older using psychosis patients (Bogaty et al., 2018).  
Despite correlation between lifetime cannabis use and subsequent (relatively) 
superior cognition in some psychosis patients, there is very limited research focusing on 
the critical period during which both illness-onset and drug-onset occurs. This suggests that 
there may be different phenotypes among older individuals with chronic psychotic 
disorders. However, relatively little is known about the cognitive profiles in the context of 
cannabis use in younger individuals with early psychosis. Prevalence of psychosis in pre-
pubertal children is relatively rare (Thomsen, 1996), although the incidence of first episode 
psychosis rapidly increases after the age of 15 years, with the highest rate of a first episode 
between the ages of 15 and 25 years (Amminger et al., 2006; Gillberg et al., 1986; Hare et 
al., 2010). Young people, aged 12 to 24 years, represent an important population in which 
to study psychotic disorders, as such individuals represent a subgroup of patients less likely 
to be exposed to critical environmental factors such as chronic use of antipsychotic 
medication (Epstein et al., 2014). There is also evidence that the corpus callosum, the 
highest order and latest maturing network of the brain, continues to grow until the middle 
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20’s (i.e. 25.45 years on average) (Pujol et al., 1993). This, as well as synaptic pruning, 
which also continues until the mid-20’s, suggests full brain development is incomplete until 
around 25 years of age (Andersen, 2003). Such a graded pattern of brain maturation means 
that development of processes such as behavioural inhibition are deferred until later 
adolescence and early adulthood (Paus, 2005), placing young people at pronounced risk for 
substance initiation and future abuse, particularly among those with substance onset prior 
to ~15 years (Pitkanen, Lyyra, & Pulkkinen, 2005).  
Given the above-mentioned literature, the present study aimed to determine the 
neurocognitive effects of current cannabis use in young psychosis patients during the 
critical period often-encompassing both drug- and illness-onset. Based on previous 
evidence, we expected no significant neurocognitive differences between cannabis-using 
and cannabis-naïve psychosis patients. However, it was expected both groups would 
underperform compared to controls.  
3.3 Methods 
Participants  
One-hundred-and-three outpatients (aged 16-25) were recruited from one of two 
Sydney-based headspace sites, a service providing specialized assessment and early 
intervention for mental health problems in young people (Scott et al., 2009). Included 
patients were diagnosed with a primary psychotic disorder by a psychiatrist according to 
DSM-IV-TR criteria (A.P.A., 2013). Proportions of primary diagnoses were: first-episode 
psychosis (n = 36); psychotic disorder NOS (n = 24); schizophrenia (n = 23); 
schizophreniform disorder (n = 8); and schizoaffective disorder (n = 12). Sixty-three 
control subjects were recruited for comparison. Exclusion criteria were: i) neurological or 
physical illness known to impinge upon cognitive or neural function (e.g. epilepsy); ii) 
history of a sustained head injury (loss of consciousness > 30 minutes); iii) insufficient 
English-language ability; and iv) premorbid IQ < 70. Three patients were subsequently 
excluded for having an illness known to impinge upon neural function (i.e. epilepsy, 
cancer), and one for a traumatic head injury.  
The assessment protocol was approved by the University of Sydney Human 
Research Ethics Committee, and written confirmed consent was collected. The healthy 
control group (N = 63; aged 16 to 25 years) was recruited from the community in the same 
metropolitan geographic area as the outpatients, and were screened for psychopathology 
by a research psychologist through a clinical interview.  
Clinical Assessment  
A self-report questionnaire was administered querying demographic, clinical and 
functional information. Questions collected age, gender, years of education, occupational 
status, personal and familial medical and psychiatric history, and medication status. A 
trained research psychologist conducted a structured clinical interview, the BMRI 
Structured Interview for Neurobiological Studies (Lee et al., 2013), to determine the nature 
and history of any mental health problems. All research psychologists were thoroughly 
trained by masters- or doctorate-level clinical psychologists or neuropsychologists. The 
interview included the expanded 24-item Brief Psychiatric Rating Scale (BPRS; (Ventura, 
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Green, Shaner, & Liberman, 1993)) and the 17-item Hamilton Depression Rating Scale 
(HDRS; (Hamilton, 1967)) to quantify general psychiatric and depressive symptoms at the 
time of assessment. Current and historical substance use was also recorded using the 
Alcohol, Smoking and Substance Use Involvement Screening Test, Version 2 (ASSIST-2). 
We focused on ‘clinically-significant’ substance use, which was operationalized as: daily 
or almost daily tobacco use, weekly or more frequent cannabis use, and weekly or more 
alcohol use. The Social and Occupational Functioning Assessment Scale (SOFAS; 
(Goldman, Skodol, & Lave, 1992)) was also used as a rating of the patient’s functioning 
from 0 to 100, with lower scores indicating more severe impairment. Participants also 
completed WHO-QoL BREF (Skevington, Lotfy, & O'Connell, 2004), which measures 
four domains (physical; psychological; social and environment) quality of life.  
Neuropsychological Assessment  
Pre-morbid intelligence (‘predicted IQ’) was estimated on the basis of performance 
on the Wechsler Test of Adult Reading (WTAR; (Wechsler, 2001)) ‘Psychomotor speed’ 
was assessed using the Trail-Making Test – part A (TMT A), with ‘mental flexibility’ 
assessed by part B (TMT B; (Strauss et al., 2006)). ‘Verbal learning’ and ‘verbal memory’ 
were assessed by the Rey Auditory Verbal Learning Test (RAVLT; (Strauss et al., 2006)) 
sum of trial 1-5 (RAVLT sum) and 20-minute delayed recall (RAVLT A7), respectively. 
FAS letters test measured ‘verbal fluency’ (Patterson, 2011). Participants also completed 
various subtests from the Cambridge Neuropsychological Test Automated Battery 
(CANTAB; (Sahakian & Owen, 1992)). Specifically, ‘sustained attention’ was indexed by 
the A-prime (sensitivity to the ‘target’) and speed of response (‘latency’) measure of the 
Rapid Visual Processing task (RVP), ‘motor and mental response’ was indexed by the 5- 
choice Movement and Reaction Time variants of Reaction Time (RTI), ‘set-shifting’ was 
indexed by Intra-Extra Dimensional Shift (IED) and ‘visuospatial learning and memory’ 
was indexed by the total adjusted errors score from the Paired Associate Learning task 
(PAL errors).  
Statistical Analyses  
Statistical analyses were performed using the Statistical Package for the Social 
Sciences (SPSS; (IBM, 2012)). To control for the effects of age (and education for RAVLT 
performance), neuropsychological variables were converted to demographically-corrected 
standardised scores (z-scores) using the following established norms: TMT (Tombaugh, 
Rees, & McIntyre, 1998) and RAVLT (Rickert & Senior, 1998). Similarly, CANTAB z- 
scores, based on an internal normative database of 3000 healthy volunteers 
(http://www.camcog.com), were calculated for each participant. Prior to analyses, outliers 
with a z-score beyond ±4.0 for each neuropsychological variable were curtailed to values 
of +4.0 or -4.0 (depending on the direction) so that the results were not disproportionately 
skewed by individuals with extreme scores. We restricted the analyses to only the 
neuropsychological tests with less than 15% of curtailed cases. The number of cases beyond 
±4.0 exceeded 10% only for PAL (14%), and IED (26%). IED was therefore removed from 
analyses. Differences in demographic, clinical and neuropsychological measures across the 
three groups were assessed using one-way analysis of variance (ANOVA). Levene’s test 
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was used to test for homogeneity of variance, and Welch’s statistic was calculated, 
correcting for degrees of freedom (df) and p-values, if and where this assumption was 
violated. The Scheffe test was used to determine post-hoc pair-wise comparisons between 
the three groups. Chi-square test was used to compare the ratio of females to males, 
smoking status, and alcohol status across groups. In any case where the two clinical groups 
were significantly different in demographic information or substance use (other than 
cannabis), a one-way ANCOVA was conducted to determine statistically significant 
differences between the groups on clinical and neuropsychological results, controlling for 
the differences in demographics or substance use.  
3.4 Results 
Three groups were subsequently formed: 63 controls were identified from a healthy 
population; 79 as patients with psychosis and no history of cannabis use; 24 as patients 
with comorbid psychosis and cannabis use. As shown in Table 1, there were no significant 
differences among the psychosis groups in terms of the distribution of sex, age, or predicted 
IQ. The two patient groups did, however, have significantly less years of education, and 
greater ratios of males to females than the control group (as is common in psychosis 
cohorts; (Ochoa et al., 2012). There were significant between-group differences for socio-
occupational functioning (SOFAS), current depressive (HDRS) and general psychiatric 
(BPRS) symptoms as well as quality of life (QoL) with both psychosis groups (i.e. with or 
without cannabis use) exhibiting worse scores on each of these measures compared to the 
healthy control group. However, the clinical groups only differed from each other in BPRS 
negative symptoms, with cannabis-naive patients scoring lower than the comorbid 
cannabis-using patients (p = 0.03). Although the two psychosis groups did not differ in age 
of psychosis onset (p = 0.98), comorbid psychosis patients were significantly more likely 
to be current nicotine smokers and consume alcohol at least weekly compared to patients 
who did not engage in cannabis use (both p < 0.01). A one-way ANCOVA determined that 
the two psychosis groups did not differ in severity of negative symptoms when controlling 
for alcohol consumption (F[1,49] = 0.24, p = 0.63), or smoking status (F[1,75] = 2.84, p = 
0.10).  
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Table 3-1: Mean scores (± standard deviation) for clinical and psychosocial variables in psychosis 
patients who currently use cannabis (PSY+CAN), psychosis patients who have never used cannabis 
(PSY-CAN) and Control groups. 
 
Note: Corresponding results for #chi-squared [df=2,166] or ANOVA [df=2,165]; *** 
denotes p<.001; ** denotes p<.01; * denotes p<.05]. Effect sizes (d statistic) for each pair-
wise group comparison [† denote large effect sizes i.e. d>0.8]. 
PSY+CAN = comorbid psychosis and current cannabis use; PSY-CAN = psychosis diagnosis with 
no cannabis use; SOFAS = social and occupational functioning assessment scale; BPRS = brief 
psychiatric rating scale; HDRS = Hamilton depression rating scale; QoL = quality of life.  
 
The neuropsychological profiles (mean z-scores) for all three groups are depicted in 
Figure 1, and the ANOVAs with corresponding Scheffe’s post-hoc tests are summarised in 
Table 2. There were no significant differences between the two psychosis groups in any of 
the 11 cognitive tests. Both clinical groups performed significantly worse than controls in 
TMT-B, RVP-A, RAVLT sum, RAVLT-A7, and PAL. Additionally, psychosis patients 
without cannabis use underperformed compared to controls in TMT-A and RTI reaction 
time, while comorbid cannabis-using patients were significantly worse in COWAT.  
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Figure 3-1: Mean scores of comorbid cannabis patients, cannabis-naive patients, and controls for 
each cognitive test. 
Note: Scores are expressed as z-scores.  
 
Table 3-2: Z-statistic mean scores (± standard deviation) for neuropsychological variables in 
PSY+CAN, PSY-CAN and Control groups. 
 
Note: Corresponding results (F statistic) for ANOVA [df=2,162; *** denotes p<.001; ** 
denotes p<.01; * denotes p<.05]. Effect sizes (d statistic) for each pair-wise group 
comparison. ‘p’ represents the P values for comparisons between the PSY+CAN and PSY-CAN 
groups. Bold values indicate comparisons that were significantly different between the PSY+CAN 
and the PSY-CAN groups. 
TMT = Trail making test; RVIP = Rapid visual information processing; RAVLT = Rey auditory 
verbal learning test; PAL = Paired associate learning; RTI5 = Choice reaction time (5-choice); 
COWAT = Controlled oral word association test.  
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3.5 Discussion 
The present study determined neurocognitive profiles of young (i.e. 16-25 years) 
psychosis patients with and without concurrent cannabis use. We found that cannabis-using 
and cannabis-naïve psychosis patients did not significantly differ across any of the 
cognitive domains. Both groups, however, performed significantly worse across a majority 
of cognitive tasks compared to controls. We have previously demonstrated that current 
cannabis-using adult patients exhibit deficits across tests of premorbid IQ, current IQ, 
verbal learning, verbal working memory, and motor inhibition, compared to non-using 
psychosis patients (Bogaty et al., 2018). However, we also observed that older age was 
predictive of worse performance in some cognitive measures, specifically processing 
speed, sustained attention, and verbal memory, with superior performance in verbal 
learning and verbal fluency. Based on studies involving adult psychosis patients, as well as 
those using healthy adult participants with current cannabis use, it would be expected that 
patients with comorbid cannabis use would perform worse across several cognitive 
domains than their non-using counterparts; however, that is not the case in the present 
study. On the other hand, de la Serna and colleagues found FEP patients, explicitly young 
adults between the ages of 9 to 17 years, who had used cannabis in the previous month 
outperformed non-users only in tests of Continuous Performance Task (CPT), or selective 
attention (de la Serna et al., 2010). There is however also evidence that suggests psychosis 
patients’ cognition is instead mediated by their clinical diagnoses.  
The present study dovetails with recent observations of no significant cognitive 
differences between adult patients with or without current cannabis use, or even with 
lifetime use (Waterreus et al., 2017). However, when taking into account clinical 
groupings, Waterreus and colleagues observed a significant negative relationship between 
current cannabis use and cognitive performance in patients with affective psychosis, but 
not in patients with non-affective psychosis. The diverse cognitive outcomes of psychosis 
patients based on distinct clinical groupings provides some support for the notion of 
alternative psychopathophysiological pathways to psychosis. For instance, it has been 
suggested that children or young people who are genetically vulnerable, and are exposed 
to cannabis especially at a young age, are more susceptible to a diagnosis of psychosis, and 
eventually schizophrenia, than if they don’t engage in cannabis use (Hall & Degenhardt, 
2008; Malone et al., 2010; Semple, McIntosh, & Lawrie, 2005). Therefore, while there are 
patients who develop psychosis regardless of external factors such as drug use (specifically 
cannabis) there appears to be a distinct group of psychosis patients who develop (non-
affective) psychosis if they engage in cannabis use, particularly during adolescence. 
Previous analyses have revealed subgroups of psychoses patients based purely on their 
family history of illness, drug use, and neurocognitive results (Crouse, Moustafa, Bogaty, 
Hickie, & Hermens, 2018; Pearlson, 2015; Tamminga et al., 2014; Tamminga et al., 2017).  
In one such line of inquiry, Crouse and colleagues performed a cluster analysis using 
patients determined to have early psychosis-spectrum illnesses (Crouse et al., 2018). They 
observed an appropriate clustering of patients into three discrete groups, one with near- 
normal cognitive performance (“Cluster 1”), one with mixed performance (“Cluster 2”), 
and one that was grossly impaired (“Cluster 3”). Most interesting from this study was the 
over representation of bipolar patients in Cluster 1, and of schizophrenia-spectrum illness 
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(i.e. schizophrenia, schizoaffective disorder, FEP) in Cluster 3. Although they found no 
significant differences in drug and alcohol use between the clusters, it is possible the 
substantial overrepresentation of affective psychosis in Cluster 1, and of non-affective 
psychosis in Cluster 3 confounded these results, as previous studies have indicated (Helle, 
Løberg, Gjestad, Schnakenberg Martin, & Lysaker, 2017; Løberg et al., 2014; Waterreus 
et al., 2017). As patients in the present study have a primary diagnosis of psychosis, rather 
than bipolar or an affective-psychosis diagnosis, Crouse and colleagues’ results closely 
follow the outcomes in the present study. There appears to be considerable evidence to 
suggest non- affective psychosis patients demonstrate significant impairments in cognition 
compared to their affective psychosis peers (Crouse et al., 2018). It may be important to 
consider these diagnostic subtypes as a key factor in our understanding of concurrent 
psychosis and cannabis use. The susceptibility to non-affective psychosis in vulnerable 
cannabis-using individuals has been further investigated in recent years.  
Current research examining associations between non-affective psychosis and 
early cannabis use tend to note two distinct subgroups after comparing the 
‘endophenotypes’ of patients, specifically neurocognition, drug use, and family history of 
illness (Pearlson, 2015). In particular, the Bipolar-Schizophrenia Network on Intermediate 
Phenotypes (B-SNIP) study suggests an emerging biotype of psychosis centred between 
traditional schizophrenia and affective psychotic disorders (Hill et al., 2013; Tamminga et 
al., 2014; Tamminga et al., 2017). This biotype appears to be associated with higher 
cannabis use, better cognition, and lower percentage of affected relatives. It is plausible 
that Cluster 2 in Crouse et al.’s research, and this intermediate biotype discovered in the B-
SNIP study, represent an alternative pathway to psychosis, in which vulnerable individuals 
have their psychotic illness precipitated by cannabis use. These patients would possibly 
have superior premorbid IQ, as well as better cognition, compared to their peers who would 
develop schizophrenia regardless of drug use, as the latter group may be more likely to 
have followed a neurodevelopmental trajectory involving aberrant cognitive development. 
The results in the present paper are in line with this theory, as the patients in the two clinical 
groups (i.e. current cannabis users, and cannabis-naive patients) demonstrate no significant 
differences in any neuropsychological tests. As fore mentioned, adult patients who are 
current cannabis users appear to underperform in cognitive tests compared to never-using 
patients. Thus, young patients who are current cannabis users would also be expected to 
underperform, however this is not the case. It appears during the early stages of illness- and 
drug-onset, when patients are considered adolescents or young adults (i.e. 16-25 years), 
their cognitive capabilities are superior to peers who will develop psychosis without 
cannabis use, however they may become comparable when the former group engage in 
protracted cannabis use. This is further supported by evidence observing the acute and 
residual effects of cannabis on neurocognition. Individuals demonstrate significant 
impairment across attention, decision making, impulsivity and working memory up to 6 
hours after use. However, even residual and long-term effects of cannabis can last days, 
affecting most areas of cognitive functioning. Unexpectedly, longer periods of abstainence 
demonstrate the most advanced improvement in cognition (Crean et al., 2011). 
Much of the research investigating comorbid psychosis and cannabis focuses on 
patients with lifetime, but not current, cannabis use, and has found superior cognitive 
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abilities in cannabis users rather than the cannabis-naive patients (Hanna, Shalvoy, et al., 
2016; Løberg & Hugdahl, 2009; Potvin et al., 2008; Rabin et al., 2011; Yücel et al., 2012). 
It appears the effect of cannabis on cognition in patients with non-affective psychosis is 
age-related. Current cannabis use seems to influence cognition more negatively, while past 
drug may be a marker of a different pathway to psychosis. This is supported by previous 
studies that demonstrate patients with early-onset cannabis use actually demonstrate better 
cognitive abilities than their peers with later-onset or who are cannabis-naïve (Jockers-
Scherübl et al., 2007; Yücel et al., 2012)  The cannabis-using patients may constitute a sub-
group with less cognitive vulnerability; cannabis use may have a more temporary influence 
on cognition, generating a short-term cognitive and psychotic episode. Thus, cannabis use 
may create transient deficits in cognition paralleling the period of acute psychosis.  
As expected, cannabis users were significantly more likely to be both nicotine 
smokers and alcohol users (Behrendt et al., 2012; Faeh, Viswanathan, Chiolero, Warren, & 
Bovet, 2006; Hermens et al., 2013; Hindocha et al., 2015). While cigarette smoking is 
associated with concurrent cannabis dependence, there is also evidence to suggest that 
nicotine mediates the relationship from only cannabis use to dependence in young people 
(Hindocha et al., 2015). Similarly, Hermens and colleagues demonstrated young adults 
with early-onset illness are particularly at risk for alcohol and substance misuse (Hermens 
et al., 2013). Evidently, there appears to be a relationship between cannabis use with 
cigarette smoking and alcohol, however both the individual effects of alcohol and cigarette 
smoking, as well as the combined effects of all three, may confound studies looking to 
observe effects of cannabis use alone.  
This highlights the first limitation in our study. As we were unable to quantify the 
quantity of cannabis, nicotine and alcohol differences in patients, we were unable to 
accurately determine the influence alcohol and nicotine use had on the patients. Similarly, 
we relied on self-report measures of drug and alcohol use. It may be beneficial to measure 
these external factors such as cannabis and alcohol use by objective means (e.g. 
radioimmunoassay) to determine more accurately a patient’s drug use, as not all properties 
of drug use (e.g. quantity, daily sessions, frequency, age of onset) were available for all 
patients. Future studies should attempt to tease out these combined effects, or determine 
the quantity and frequency of these additional drugs to evade confounding effects, as well 
as attempt to complete the DFAQ-CU (Daily Sessions, Frequency, Age of Onset, and 
Quantity of Cannabis Use Inventory; (Cuttler & Spradlin, 2017)) for more accurate and 
consistent results across cannabis-related studies. Likewise, as previous studies have 
demonstrated the significance of age of cannabis-onset, it would provide advantageous to 
have had this information for all individuals. Unfortunately we were unable to run any 
analyses as this information was only available for a handful of patients. Finally, 
outpatients were help-seeking and may not be comparable to individuals in the community 
who do not seek help for various reason (e.g. lower insight).  
In conclusion, these results support the notion of an alternative pathway to 
schizophrenia by cannabis use in vulnerable individuals. This phenomenon appears to be 
time-related, with older, chronic schizophrenia patients who have lifetime, but not current, 
cannabis use exhibiting superior cognition compared to cannabis-naive patients, yet these 
two subgroups demonstrate equal cognition at the time of both illness- and drug-onset. 
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Targeting pharmacological and cognitive remediation treatments to this individual 
subgroup of non-affective psychoses patients may prompt improved pathological 
outcomes.  
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Chapter 4  
4. Summary, Discussion and Future Work 
4.1 Summary of studies in this thesis 
Study 1: Meta-analysis of neurocognition in psychosis patients with current cannabis 
use 
This study analysed neuropsychological data from 14 studies to determine if age 
mediated cognitive results between patients with cannabis use, and patients with no history 
of cannabis use. Overall, these results indicate cognitive deficits in comorbid psychosis 
patients compared to cannabis-naïve patients, however this study also established a 
significant link between patient age and cognition in current cannabis-using patients. 
Analyses and meta-regressions were carried out to determine the effect sizes of results 
across studies. The mean age of patients ranged from 16 to 37 years of age. Compared to 
non-users, patients with cannabis use underperformed across tests of premorbid and current 
IQ, verbal learning, verbal working memory, and motor inhibition. Interestingly, the 
association of cannabis use and age was varied, with increasing age being predictive of 
worse performance in processing speed, sustained attention, verbal memory, and better 
performance in verbal learning and verbal fluency.  
Study 2: The neuropsychological profiles of young psychosis patients with and 
without cannabis use 
This study explored potential disparities in cognition between young (i.e. between 
16 and 25 years of age) non-affective psychosis patients with and without current cannabis 
use. The cognitive profile of young cannabis-using psychosis patients does not appear to 
differentiate from young cannabis-naïve  patients, despite their drug use. Subjects consisted 
of 24 cannabis-using and 79 cannabis-naïve patients, matched on age. Although healthy 
controls outperformed both psychosis groups across most cognitive measures, there were 
no significant differences between the two clinical groups. These results contrast the 
findings of cannabis-using, but otherwise healthy, individuals who display cognitive 
deficiencies compared to non-using counterparts. Thus, indicating underlying 
neuropsychological mechanisms involved in a distinct cannabis-initiated pathway.  
4.2 The Overall Findings: Implications for Existing Models  
The primary aim of this thesis was to investigate and compare the neurocognition 
of young psychosis patients who either currently use, or who have no history of using, 
cannabis. It was hypothesized that young patients who concurrently use cannabis would 
exhibit cognition equal to that of their drug-naïve peers, which was wholly supported by 
the results of the second study. The most consistent finding in this series of studies was that 
neurocognitive results appeared to be moderated by patient age. Interestingly, although 
comorbid adult patients demonstrated significant cognitive deficiencies across a range of 
domains compared to adult patients without a history of drug use, young comorbid patients 
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instead exhibited no cognitive differences compared to their drug-naïve peers. Specifically, 
in the first study (i.e. Chapter 2), comorbid patients underperformed in tests of premorbid 
and current IQ, verbal learning, verbal working memory, and motor inhibition. This 
shortfall is typically observed in comorbid older, more chronic patients, as well as 
otherwise healthy, cannabis-using individuals (Crean et al., 2011; Hall & Lynskey, 2016; 
Løberg & Hugdahl, 2009; Shrivastava, Johnston, & Tsuang, 2011). Interestingly, as Løberg 
and Hugdahl have shown, once cannabis-using patients cease drug use, they actually 
demonstrate global cognition that is superior to patients who have no history of drug use 
(Løberg & Hugdahl, 2009). In fact, several studies have investigated this paradoxical 
phenomenon, consistently reporting that patients with a history of cannabis use, but 
currently abstain, outperform their drug-naïve peers (Cunha et al., 2013; González-Pinto et 
al., 2016; Hanna, Shalvoy, et al., 2016; Helle et al., 2014; Helle et al., 2017; Waterreus et 
al., 2017; Yücel et al., 2012). Importantly, the first study revealed significant differences 
in global cognitive results was moderated by patient age, where an older age generally 
correlated with worse performance in comorbid psychosis patients (Bogaty et al., 2018). 
This finding is further emphasized in the second study, which demonstrated no significant 
cognitive differences between young (i.e. between 16 and 25 years of age) patients with 
and without concurrent cannabis use.  
Cognitive deficits are recognized as a core feature of psychosis, particularly 
schizophrenia-spectrum disorders. These deficits often present before illness-onset (Kahn 
& Keefe, 2013; Woodberry, Giuliano, & Seidman, 2008) and persist after treatment of 
clinical symptoms (Caspi et al., 2003). The cognitive deficiencies seen across non-affective 
psychosis patients are extensive, demonstrating significant deficits across tests of memory, 
attention, motor skills, executive function, and intelligence (Bora et al., 2009; Bora et al., 
2010; Bowie & Harvey, 2006; Fioravanti, Bianchi, & Cinti, 2012; O'Carroll, 2000). 
Cognitive impairment is considered a core feature of schizophrenia as patients normally 
exhibit deficits between 1 and 2 standard deviations. In fact, cognitive performance is 
considered more predictive of a patient’s functional outcome than positive symptoms 
(Bowie & Harvey, 2006; M. F. Green & Harvey, 2014; Harvey, Koren, Reichenberg, & 
Bowie, 2006). The acute and long-term effects of cannabis in healthy populations has been 
well documented, with individuals typically displaying impairments across memory, 
learning, and working memory compared to non-users, and is more severe with younger 
drug-onset and heavier cannabis use (Grant et al., 2003; Schweinsburg, Brown, & Tapert, 
2008). However, comorbid non-affective psychosis patients instead demonstrate counter-
intuitive results, both when cannabis use has ceased (Bora et al., 2009; Coulston et al., 
2007; Yücel et al., 2012), and when it is still concurrent, as seen in this thesis. 
This moderation of cognition by age is of particular interest, as it dovetails previous 
research that suggests there is a ‘window of vulnerability’ for cannabis use in a subgroup 
of psychosis patients. Jockers-Scherübl et al. exemplified this result by showing psychosis 
patients who began using cannabis before the age of 17, but later abstain, exhibit better 
cognition than patients who have a drug-onset after 17 years (Jockers-Scherübl et al., 2007). 
Yücel and colleagues similarly found an early initiation of cannabis use correlated with 
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superior cognitive performance in first-episode psychosis patients (Yücel et al., 2012). 
Interestingly, more frequent or moderate use of cannabis has also been associated with 
improved neurocognition in patients (Schnakenberg Martin et al., 2016; Schnell et al., 
2009a). A number of theories have been suggested to explain this paradoxical finding. 
Initially, it was thought this group of patients required superior social skills in order to gain 
access to an illegal drug (Potvin et al., 2008; Solowij & Michie, 2007). However, this is 
unsupported by evidence, which suggests patients who also engage in drug use present with 
poorer premorbid functioning (P. A. Ringen et al., 2008), as well as poorer premorbid 
academic functioning (Larsen et al., 2006). It has also been proposed that cannabis instead 
exhibits a neuroprotective effect, specifically when consumed prior to illness-onset. 
Psychosis patients with a history of cannabis use have been found to have significantly 
higher concentrations of nerve growth factor (NGF) and brain-derived neurotrophic factor 
(BDNF) (Jockers-Scherübl et al., 2004; Jockers-Scherübl et al., 2003). As these 
neurotrophins are involved in the development and maintenance of function of nerve cells, 
their increased presence in cannabis users who later develop schizophrenia may correspond 
to an endogenous repair system for impaired nerve cells. Thus cannabis may induce this 
repair mechanism, which in turn preserves cognitive function (Jockers-Scherübl et al., 
2007). This is supported by both non-clinical and other clinical (non-psychotic) studies that 
demonstrate neuroprotective effects of cannabis (Hampson et al., 2000; Ramírez et al., 
2005). Giuffrida et al. similarly found cerebrospinal fluid (CSF) levels of an endogenous 
cannabinoid, anandamide, negatively correlated with psychotic symptoms in acute 
untreated schizophrenia (Giuffrida et al., 2004), suggesting an endogenous compensatory 
adaptation within the cannabinoid system in schizophrenia. In fact, the neuroprotective 
properties of cannabis, as well as its compensatory effect in psychosis patients needs to be 
further researched to better understand the complex relationship. However, the present 
thesis explored this third and perhaps, most convincing concept of cannabis use by patients.  
Much of the current research suggests psychosis patients who have a history of 
long-term cannabis use increased their risk of developing psychosis through early initiation 
of drug use. Ideally, this subgroup of patients would not have developed psychosis in the 
absence of cannabis (Løberg et al., 2014; Schnell et al., 2009a; Yücel et al., 2012). In other 
words, cannabis may induce psychosis in less cognitively vulnerable individuals, while 
non-users who develop psychosis likely have a greater genetic vulnerability to psychosis 
and thus manifest poorer cognitive performance at psychosis onset. This is especially 
supported by Yucel et al.’s and Jockers-Scherübl et al.’s findings of superior cognition in 
comorbid patients who have an earlier onset of cannabis use, compared to patients with 
later cannabis-onset or who are drug-naïve (Jockers-Scherübl et al., 2007; Yücel et al., 
2012). Additionally, Arseneault and colleagues report that cannabis use before the age of 
15 years significantly increases the risk of developing subsequent psychosis (Arseneault et 
al., 2002; Arseneault, Cannon, Witton, & Murray, 2004). Interestingly, cannabis users at 
first-episode have fewer neurological soft signs than non-users (Ruiz-Veguilla et al., 2009), 
further indicating cannabis users have less neurodevelopmental impairment. Moreover, as 
evidence shows that patients who engage in more moderate and frequent cannabis use 
actually exhibit better cognition (Núñez et al., 2016; Schnakenberg Martin et al., 2016), it 
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can be speculated that a greater magnitude of toxic insult is required to induce psychosis in 
individuals who are particularly invulnerable to psychosis. Conversely, there is data to 
suggest cannabis-using patients actually present with structural brain abnormalities not as 
severely observed in non-users. Rapp et al.’s review found that areas concentrated with 
cannabinoid receptors, such as the cingulate and prefrontal cortices, are particularly 
susceptible to injury (Rapp, Bugra, Riecher-Rössler, Tamagni, & Borgwardt, 2012). Two 
studies have also shown that comorbid patients tend to have reduced cortical thickness 
compared to non-users (Habets, Marcelis, Gronenschild, Drukker, & van Os, 2011; Rais et 
al., 2010). However, these studies present some important limitations, predominantly that 
their subjects were diagnosed with established, chronic schizophrenia, and often included 
comorbid alcohol and other substance use, which is likely to confound results. One way to 
eradicate this issue is to focus on first-episode patients, particularly young people who have 
less exposure to environmental effects, such as antipsychotic medications and other 
substance use. Interestingly, a mixed-model analysis of 10-yearlong sample shows 
neurocognitive stability in patients over time (Rund et al., 2016). It reported that patients 
with stable remission in the first year had better neurocognitive trajectory in the follow-ups 
than patients who remained psychostic after the first year. Patients also did not deteriorate 
significantly compared to controls after treatment at the 10-year follow-up period, 
indicating cognitive change occurs early on in the illness.  
The second study in the present thesis demonstrates support for the latter theory of 
an alternate pathway to psychosis. While a plethora of studies report significant cognitive 
deficiencies in healthy individuals who use cannabis, as well as comorbid adult psychosis 
patients, concurrent young patients showed no cognitive differences compared to young 
non-users. This counter-intuitive finding indicates spared neurocognition in young users 
even at the first-episode. These results parallel Tamminga and colleagues’ extensive 
research into psychoses phenotypes, particularly the Bipolar and Schizophrenia Network 
on Intermediate Phenotypes (B-SNIP) studies (Tamminga et al., 2014; Tamminga et al., 
2017). Importantly, evidence provided by the B-SNIP study shows there are clusters of 
individuals with shared biological features (known as ‘bio-types’) despite there being a 
commingling of their traditional clinical phenotype (i.e. schizophrenia or affective 
psychoses disorders) (Hill et al., 2013; Tamminga et al., 2014). Notably, one of the three 
biotypes identified appears to be associated with higher cannabis use, better cognition, and 
lower percentage of affected relatives (Tamminga et al., 2017). Especially because age of 
drug use-onset appears to moderate neurocognition later in life, previous studies have 
suggested a ‘window of vulnerability’ exists in which cannabis use during a specific age 
frame, explicitly during adolescence, increases the risk of invulnerable young people to 
develop psychosis.  
 The main psychoactive component of cannabis, tetrahydrocannabinol (THC), has 
been shown to affect the endogenous cannabinoid and dopamine systems by interacting 
with cannabinoid receptors (Bossong & Niesink, 2010; D’Souza et al., 2005; Solowij & 
Michie, 2007). Kuepper et al. suggest intake of cannabis increases dopamine levels across 
several areas of the brain implicated in schizophrenia, including striatal and prefrontal 
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regions (Kuepper et al., 2010). Specifically, as THC is a cannabinoid receptor 1 (CB1) 
agonist, cannabis likely influence CB1 receptors on GABA and glutamate. This would 
influence the midbrain dopamine neurons and prefrontal cortical pyramidal cells. Thus by 
increasing dopamine concentration in striatal regions of the brain, THC, when repeatedly 
administered, decreases dopamine levels in prefrontal regions of the brain via sensitization 
processes resulting in expressions of a psychotic disorder (Kuepper et al., 2010). The 
repeated administration of THC alters the functioning of the prefrontal cortex, a region 
implicated in schizophrenia, by acting on dopamine signaling via activation of CB1 
receptors. Interestingly, Schneider and Koch found more irreversible residual effects in 
prepubertal rats after chronic exposure to THC as compared to more mature rats (Schneider 
& Koch, 2003). Correspondingly, an earlier age of psychosis onset tends to occur in 
patients who have a history of cannabis use (Barnes et al., 2006; Donoghue et al., 2014; 
Large, Sharma, Compton, Slade, & Nielssen, 2011; H. Myles et al., 2016; N. Myles, 
Newall, Nielssen, & Large, 2012; Power, Dragovic, Jablensky, & Stefanis, 2013; Tosato et 
al., 2013), and patients who had been using high-potency cannabis everyday had the earliest 
onset (Di Forti et al., 2014). Evidently, cannabis use during adolescence presents with some 
unique consequences likely not observed in later onset of drug use. There also appears to 
be a stronger relationship between adolescent cannabis use and psychosis compared to adult 
use, supporting this neurodevelopmental hypothesis (Caspi et al., 2005; Konings, Henquet, 
Maharajh, Hutchinson, & Van Os, 2008). The endocannabinoid system is particularly 
involved in key processes of brain maturation during adolescence, and levels of 
endocannabinoids and cannabinoid receptors increase at this age (Schneider, 2008). 
Exposure to cannabis during critical neurodevelopmental stages potentially influences the 
endocannabinoid system and other key neurotransmitter systems. This may explain the 
paradoxical cognitive findings in psychosis patients with a history of cannabis use.  
  Several longitudinal studies, as well as meta-analyses, have indicated the existence 
of a gene by environment interaction in the development of psychosis in a subgroup of 
patients. Schizophrenia itself appears to be a highly heritable illness (Shih, Belmonte, & 
Zandi, 2004), however as Harrison reports, genes typically contribute no more than 50% to 
etiology, suggesting environmental factors considerably influence the development of 
schizophrenia (P. J. Harrison, 2015). Keshavan has also put forward a “multihit” theory 
around schizophrenia development, which suggests brain insults during the critical period 
of adolescence would increase the rate of subsequently developing schizophrenia 
(Keshavan, 1999). It’s suggested early illness-onset, as seen in young people, may be the 
result of excessive synapse elimination, as well as dopaminergic over activity. The 
catechol-O-methyltransferase (COMT) enzyme in particular has been referred to as a 
constituent of the gene x environment model of schizophrenia. Caspi et al.’s longitudinal 
study found a functional polymorphism in the COMT gene moderated the influence of 
adolescent cannabis use on developing psychosis later on (Caspi et al., 2005). That is, 
carriers of the valine158 allele were more likely to display psychotic symptoms and to 
develop schizophrenia-spectrum illness if they used cannabis. Importantly, COMT is the 
prime enzyme involved in the metabolism of dopaminergic transmission in the prefrontal 
cortex (Tunbridge, Weinberger, & Harrison, 2006). Animal models have similarly 
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demonstrated the influence of the interaction between THC and the COMT gene in 
developing schizophrenia. Behan and colleagues found chronic THC administration in 
adolescent mice was modulated by COMT gene deletion in altering neurotransmitter 
function, and paralleled the dopaminergic and GABA-ergic functioning as seen in human 
patients (Behan et al., 2012). However, this specific genotype interaction should be 
considered carefully, as a recent study has instead found no correlation between underlying 
COMT genotype and cannabis use in developing psychotic symptoms (Zammit, Owen, 
Evans, Heron, & Lewis, 2011). 
 The complex relationship between cannabis use and subsequent psychosis 
certainly needs to be further explored. However, the general consensus of research 
available suggests a subgroup of psychosis patients may bring about their own illness 
through early onset of cannabis use. This gene-environment interaction is of particular 
interest as older, more chronic patients who have a history of cannabis, but currently 
abstain, outperform patients who have no history of cannabis use. This paradoxical finding 
contrasts cognitive results of healthy individuals who have a history of using cannabis, who 
instead demonstrate poor cognitive abilities even after stopping cannabis use. As adults, 
this subgroup who have a history of cannabis use exhibit spared cognition, however the 
research focusing on young people, specifically at the time of both illness- and drug-use 
onset, is extremely limited. The studies in this thesis contributed to the gap of knowledge 
and understanding of psychosis and drug-use clearly present in this area. Importantly, the 
first study (i.e. Chapter 2) determined cognitive functioning is moderated by current age of 
the patient. The highly variable results between younger or older patients clearly 
demonstrates research of cognitive abilities in young patients, rather than older patients 
alone, is highly warranted, particularly as this is when both illness- and cannabis-onset 
typically occur. Similarly, the second study (i.e. Chapter 3) exemplified spared cognition 
in comorbid cannabis-using patients, compared to non-using patients. This was of great 
significance as the individuals, who were between 16 and 25 years of age, generally had no 
to little exposure to additional external influences, such as other drugs and antipsychotic 
medication. Most compelling however, was that even as concurrent cannabis users, these 
patients demonstrated no cognitive deficits when compared to non-using patients. This 
contrasts studies of comorbid adults patients, as well as healthy cannabis-using indivduals. 
Therefore this thesis hopes to initiate further research into psychosis and drug use, but with 
a focus on the critical period when both illness- and drug use-onset typically occur.  
4.3 Limitations of the studies 
Neurocognitive Measures 
The use of neurocognitive measures in evaluating patient performance is not 
without its limitations. Most predominate is the debatable validity of neurocognitive 
assessments. In essence, are the tests really measuring what we think they are measuring, 
and how well do they translate to real-world settings? While both non-computerized and 
computerized neurocognitive assessment tools (NCATs) exist to measure an individual’s 
cognitive functioning, the vast majority of recent studies utilize NCATs due to their 
efficiency and absence of human error. With the influx of reliable NCATs accessible across 
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current research, more valid testing and assessments have become available that would not 
be achieved with simple pen and paper. 
The vast amount of different types of neurocognitive assessments available is 
another reason for caution. While there exist different cognitive tests for adults and 
children, adult assessments typically exclude patients under the age of 16, and so was 
disregarded in this thesis. However, each cognitive domain has a number of different tests 
that may be used to assess it. For instance, general intelligence can be measured using any 
of the following: National Adult Reading Test (NART), Wechsler Adult Intelligence Scale 
(WAIS), or the Wechsler Test of Adult Reading (WTAR). Similarly, executive functioning 
may be measured via a range tests including those that assess cognitive flexibility, concept 
formation, and problem solving. Despite the heterogeneity available across tests for 
domains, there is consistency among the cognitive domains used in these studies 
(Committee on Psychological Testing, 2015).  
Differential effects of cannabinoids 
There are several cannabinoids present within cannabis, other than THC, the main 
psychoactive component. While THC has generally been recognised as mimicking 
psychotic tendencies in its users, and is responsible for producing the ‘high’ its users feel, 
cannabidiol (CBD) is another cannabinoid with a rather prominent effect on the user. 
Importantly, the varying quantities of cannabinoids, specifically of THC and CBD, can 
affect the user’s disposition and ultimately, longterm effects of cannabis use.  
As well as quality of cannabis, dosage and frequency of use was unable to be assessed. 
This was an especially critical limitation in the second study (i.e. Chapter 3). Previous 
research has shown that a lifetime history of moderate cannabis use, rather than heavy or 
minimal use, is actually predictive of improved neurocognition in patients. Unfortunately 
these qualities were unable to be measured and thus their influences on results assessed. 
Similarly, more frequent use of cannabis (i.e. daily) by patients typically resulted in 
superior cognitive functioning that patients who abstained or who engaged in cannabis use 
less often. 
 
4.4 Future Directions 
This thesis sought to explore and contribute to a gene x environment hypothesis of 
psychosis by early cannabis onset. Evidently, there appears to underlying processes 
involved within a subgroup of psychosis patients who have admittedly brought about their 
own illness. Unfortunately, the research reporting on patients during both illness- and drug 
use-onset, typically as young people (i.e. 16 – 25 years of age), is extremely limited. In 
order to best understand the gene x environment interaction in this subgroup, whether 
through cognitive measures or neuroimaging, it would be most beneficial in observing 
patients during this delicate period. Future studies need to focus on the differences in non-
affective psychosis patients who use and abstain from cannabis during this ‘window of 
vulnerability’, especially before cannabis use ceases. 
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Additionally, there is a need for longitudinal studies in psychosis and drug 
research, in order to follow these cognitive changes over time. As shown in this thesis, 
cognitive functioning in comorbid patients appears to be mediated by patient age. 
Confounding effects of antipsychotic medications, as well as other drug use and alcohol, 
may be influential on cognitive results. Longitudinal studies may be able to show around 
what age, and why, cognitive functioning becomes more heterogenous among comorbid 
cannabis-using patients as they grow older. Importantly, however, it is also critical to 
observe how this subgroup of patients progress, both cognitively and symptomatically, 
should they be initiating their own illness-onset. Longitudinal studies will demonstrate 
psychosocial impairments likely not observed in cannabis-naive patients and also how this 
may fluctuate over time.  
4.5 Final Comment  
Evidently, cannabis use across non-affective psychosis patients presents with 
unique clinical consequences. The significant rate of cannabis use among schizophrenia 
patients similarly demonstrates cause for concern due to the neurobiological underpinnings 
of schizophrenia alone. Future advances in the field of neuroscience and genetics will have 
important implications for our understanding of this relationship, and how to best treat this 
particular subgroup of patients, as well as circumvent cases going forward. The interaction 
of vulnerability x cannabis in subsequent psychosis onset is thus critical in creating targeted 
interventions, and in doing so, further understanding the workings of distinct systems in 
the brain. 
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